BioMedLib Search Engine
[ goto HOMEPAGE ]
Don't miss relevant answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
anal carcinoma stage i 2005:2010[pubdate] *count=100
222 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
anal carcinoma stage i
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 222
1.
Martin FT, Kavanagh D, Waldron R:
Squamous cell carcinoma of the anal canal.
Surgeon
; 2009 Aug;7(4):232-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Squamous cell
carcinoma
of the
anal
canal
.
Squamous cell
carcinoma
ofthe
anal
canal
represents 1.5% of all malignancies affectingthe gastrointestinal tract.
CLINICAL MANAGEMENT: Historically abdominoperineal resection had been the treatment of choice with local resection reserved for early
stage
disease.
Work by Nigro et al. has revolutionised how we currently manage
carcinoma
of the
anal
canal
, demonstrating combined modality chemoradiotherapy as an appropriate alternative to surgical resection with the benefit of preserving sphincter function.
[MeSH-major]
Anus
Neoplasms / diagnosis.
Anus
Neoplasms / therapy.
Carcinoma
, Squamous Cell / diagnosis.
Carcinoma
, Squamous Cell / therapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19736891.001).
[ISSN]
1479-666X
[Journal-full-title]
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
[ISO-abbreviation]
Surgeon
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Scotland
[Number-of-references]
57
2.
Yamashita S, Masui T, Katayama M, Sato K, Yoshizawa N, Seo H, Sakahara H:
T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences.
J Magn Reson Imaging
; 2007 Mar;25(3):511-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
T2-weighted MRI of rectosigmoid
carcinoma
: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences.
MATERIALS AND METHODS: Forty patients (
stage
: pT0, 1; pTis-2, 15; pT3-4, 24) were included in the study.
All examinations were performed on a 1.5T magnet with a phased-array coil and the patients were studied in the prone position with per-
anal
air injection.
CONCLUSION: The BH-FRFSE sequence may be the first choice for rectosigmoid T2W imaging in the prone position with per-
anal
air injection for patients who can hold their breath stably.
[MeSH-major]
Carcinoma
/ diagnosis. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis. Respiration. Sigmoid Neoplasms / diagnosis
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17326094.001).
[ISSN]
1053-1807
[Journal-full-title]
Journal of magnetic resonance imaging : JMRI
[ISO-abbreviation]
J Magn Reson Imaging
[Language]
eng
[Publication-type]
Clinical Trial; Comparative Study; Journal Article
[Publication-country]
United States
3.
Kopriva I, Persin A:
Unsupervised decomposition of low-intensity low-dimensional multi-spectral fluorescent images for tumour demarcation.
Med Image Anal
; 2009 Jun;13(3):507-18
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Such situation arises when low-dimensional low-intensity multi-spectral image of the tumour in the early
stage
of development is represented by the SLMM, wherein tumour is spectrally similar to the surrounding tissue.
We demonstrate good performance of the method on both computational model and experimental low-intensity red-green-blue fluorescent image of the surface tumour (basal cell
carcinoma
).
MedlinePlus Health Information.
consumer health - Skin Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19282233.001).
[ISSN]
1361-8423
[Journal-full-title]
Medical image analysis
[ISO-abbreviation]
Med Image Anal
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
Advertisement
4.
Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, Yamaguchi H, Egami T, Kitada H, Tanaka M:
LIM only 4 is overexpressed in late stage pancreas cancer.
Mol Cancer
; 2008;7:93
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
LIM only 4 is overexpressed in late
stage
pancreas
cancer
.
BACKGROUND: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast
cancer
.
If so, this could result in a better understanding of tumorigenesis in pancreatic
cancer
.
METHODS: We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal
carcinoma
[IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM
carcinoma
[IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
RESULTS: 9 of 14 pancreatic
cancer
cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE).
In bulk tissue samples, expression of LMO4 was higher in pancreatic
carcinoma
than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both).
These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic
cancer
.
[MeSH-minor]
Adaptor Proteins, Signal Transducing. Analysis of Variance.
Carcinoma
, Pancreatic Ductal / genetics.
Carcinoma
, Pancreatic Ductal / pathology.
Carcinoma
, Papillary / genetics.
Carcinoma
, Papillary / pathology. Cell Line, Tumor. Humans. LIM Domain Proteins. Neoplasm Staging. Protein-Serine-Threonine Kinases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 2003 May 19;88(10):1543-8
[
12771919.001
]
[Cites]
Jpn J Clin Oncol. 2003 Feb;33(2):93-7
[
12629061.001
]
[Cites]
Pancreas. 2004 Apr;28(3):219-30
[
15084961.001
]
[Cites]
Cancer Res. 2004 May 1;64(9):3215-22
[
15126362.001
]
[Cites]
Med Electron Microsc. 2004 Jun;37(2):82-8
[
15221649.001
]
[Cites]
Am J Surg Pathol. 2004 Aug;28(8):977-87
[
15252303.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71
[
2034676.001
]
[Cites]
Oncogene. 1991 Oct;6(10):1887-93
[
1923511.001
]
[Cites]
N Engl J Med. 1992 Feb 13;326(7):455-65
[
1732772.001
]
[Cites]
EMBO J. 1994 Jul 15;13(14):3329-38
[
8045262.001
]
[Cites]
Am J Pathol. 1994 Dec;145(6):1547-50
[
7992857.001
]
[Cites]
Genes Chromosomes Cancer. 1995 Jan;12(1):24-31
[
7534107.001
]
[Cites]
Cancer Res. 1996 Jun 1;56(11):2527-30
[
8653691.001
]
[Cites]
Nat Genet. 1998 Jan;18(1):38-43
[
9425897.001
]
[Cites]
Pancreas. 1998 Apr;16(3):238-42
[
9548661.001
]
[Cites]
Am J Pathol. 1998 Jul;153(1):263-9
[
9665487.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11257-62
[
9736723.001
]
[Cites]
Biochim Biophys Acta. 1999 Apr 14;1445(1):148-53
[
10209267.001
]
[Cites]
Am J Pathol. 1999 Jun;154(6):1835-40
[
10362809.001
]
[Cites]
Gene. 2005 Jan 3;344:67-77
[
15656974.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64
[
15897450.001
]
[Cites]
Pancreas. 2005 Nov;31(4):344-9
[
16258368.001
]
[Cites]
Rocz Akad Med Bialymst. 2005;50:69-72
[
16358942.001
]
[Cites]
Biochem Biophys Res Commun. 2006 May 19;343(4):1186-90
[
16580634.001
]
[Cites]
Oncogene. 2006 May 11;25(20):2920-30
[
16331278.001
]
[Cites]
World J Gastroenterol. 2006 Jun 28;12(24):3878-82
[
16804974.001
]
[Cites]
Oncogene. 2007 Sep 27;26(44):6431-41
[
17452977.001
]
[Cites]
Br J Cancer. 2008 Feb 12;98(3):537-41
[
18231110.001
]
[Cites]
Am J Pathol. 2000 Nov;157(5):1623-31
[
11073822.001
]
[Cites]
Mamm Genome. 1999 Nov;10(11):1089-94
[
10556429.001
]
[Cites]
Pancreatology. 2008;8(6):587-92
[
18849640.001
]
[Cites]
Am J Surg Pathol. 2001 May;25(5):579-86
[
11342768.001
]
[Cites]
Am J Pathol. 2001 Dec;159(6):2017-22
[
11733352.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7
[
11734645.001
]
[Cites]
Cancer. 2002 Jan 1;94(1):62-77
[
11815961.001
]
[Cites]
J Biol Chem. 2002 Mar 8;277(10):7849-56
[
11751867.001
]
[Cites]
Int J Oncol. 2002 Nov;21(5):1067-72
[
12370756.001
]
[Cites]
Carcinogenesis. 2003 Feb;24(2):193-8
[
12584167.001
]
[Cites]
J Hepatobiliary Pancreat Surg. 2003;10(2):125-36
[
14505145.001
]
(PMID = 19099607.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / LMO4 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
[Other-IDs]
NLM/ PMC2628350
5.
Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY:
Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
World J Gastroenterol
; 2006 Jun 28;12(24):3911-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Circulating DNA level is negatively associated with the long-term survival of hepatocellular
carcinoma
patients.
AIM: To quantify the circulating DNA in plasma from patients with hepatocellular
carcinoma
(HCC) and to evaluate its prognostic value.
The circulating DNA level was closely associated with tumor size (P = 0.008) and TNM
stage
(P = 0.040), negatively associated with the 3-year disease-free survival (DFS) (P = 0.017) and overall survival (OS) (P = 0.001).
[MeSH-major]
Carcinoma
, Hepatocellular / blood.
Carcinoma
, Hepatocellular / pathology. DNA, Neoplasm / blood. Liver Neoplasms / blood. Liver Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Liver Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2003 Mar;9(3):1047-52
[
12631605.001
]
[Cites]
Int J Cancer. 2003 Jan 10;103(2):149-52
[
12455027.001
]
[Cites]
N Engl J Med. 2004 Jun 10;350(24):2461-70
[
15190138.001
]
[Cites]
Ann N Y Acad Sci. 2004 Jun;1022:17-24
[
15251934.001
]
[Cites]
Cancer Res. 1977 Mar;37(3):646-50
[
837366.001
]
[Cites]
Oncology. 1989;46(5):318-22
[
2779946.001
]
[Cites]
Cancer. 1990 Nov 15;66(10):2174-9
[
2171748.001
]
[Cites]
Mol Med. 1995 May;1(4):344-65
[
8521292.001
]
[Cites]
J Clin Oncol. 1999 Feb;17(2):578-84
[
10080602.001
]
[Cites]
Hepatology. 1999 Oct;30(4):1027-36
[
10498656.001
]
[Cites]
Nature. 1953 Apr 25;171(4356):737-8
[
13054692.001
]
[Cites]
Anal Biochem. 1999 Dec 1;276(1):59-64
[
10585744.001
]
[Cites]
J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11
[
11078757.001
]
[Cites]
Transfusion. 2001 Feb;41(2):276-82
[
11239235.001
]
[Cites]
Cancer Res. 2001 Jun 15;61(12):4675-8
[
11406535.001
]
[Cites]
Cancer Res. 2001 Aug 1;61(15):5723-6
[
11479206.001
]
[Cites]
Clin Chem. 2001 Sep;47(9):1607-13
[
11514393.001
]
[Cites]
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
[
11577478.001
]
[Cites]
World J Gastroenterol. 2002 Apr;8(2):193-9
[
11925590.001
]
[Cites]
World J Gastroenterol. 2001 Aug;7(4):445-54
[
11819809.001
]
[Cites]
Anticancer Res. 2002 Jan-Feb;22(1A):421-5
[
12017326.001
]
[Cites]
Br J Cancer. 2002 Dec 2;87(12):1449-53
[
12454776.001
]
[Cites]
Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82
[
14571790.001
]
(PMID = 16804981.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / DNA, Neoplasm
[Other-IDs]
NLM/ PMC4087944
6.
Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL:
Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
Cancer Lett
; 2010 Apr 1;290(1):49-57
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder
cancer
patient serum: Complex formation as a mechanism of inactivation.
Serum MIF in bladder
cancer
patients (TCC
stage
II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder
cancer
patient serum.
These data suggest that increased circulating levels of bioactive MIF are present in bladder
cancer
patient serum.
Genetic Alliance.
consumer health - Bladder cancer
.
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Published by Elsevier Ireland Ltd.
[Cites]
Nat Med. 2000 Feb;6(2):164-70
[
10655104.001
]
[Cites]
Mediators Inflamm. 2009;2009:535348
[
19325914.001
]
[Cites]
Transplantation. 2001 Jun 27;71(12):1777-83
[
11455258.001
]
[Cites]
Cancer. 2002 Mar 1;94(5):1449-56
[
11920501.001
]
[Cites]
Blood. 2002 Jun 1;99(11):4015-20
[
12010802.001
]
[Cites]
Anal Chem. 2002 Oct 15;74(20):5383-92
[
12403597.001
]
[Cites]
Am J Pathol. 2002 Dec;161(6):2053-63
[
12466122.001
]
[Cites]
Trends Cardiovasc Med. 2002 Nov;12(8):331-8
[
12536119.001
]
[Cites]
Immunol Cell Biol. 2003 Apr;81(2):137-43
[
12631237.001
]
[Cites]
Expert Opin Ther Targets. 2003 Apr;7(2):153-64
[
12667094.001
]
[Cites]
J Endotoxin Res. 2003;9(2):119-23
[
12803886.001
]
[Cites]
Anal Chem. 2003 Sep 1;75(17):4646-58
[
14632076.001
]
[Cites]
J Biol Chem. 2004 Apr 2;279(14):13729-37
[
14736878.001
]
[Cites]
BMC Cancer. 2004 Jul 12;4:34
[
15248897.001
]
[Cites]
J Urol. 2004 Oct;172(4 Pt 1):1504-9
[
15371880.001
]
[Cites]
Am J Clin Pathol. 1978 Feb;69(2):194-5
[
629228.001
]
[Cites]
J Clin Pathol. 1979 Jan;32(1):21-5
[
429575.001
]
[Cites]
Thromb Haemost. 1981 Aug 28;46(2):500-3
[
7302888.001
]
[Cites]
J Urol. 1982 Jul;128(1):72-4
[
7109075.001
]
[Cites]
Am J Med. 1989 Sep 11;87(3B):10S-14S
[
2552799.001
]
[Cites]
Thromb Haemost. 1996 Dec;76(6):897-901
[
8972008.001
]
[Cites]
J Biol Chem. 1997 Aug 1;272(31):19393-400
[
9235938.001
]
[Cites]
Int J Hematol. 1998 Jul;68(1):67-78
[
9713170.001
]
[Cites]
BMC Cancer. 2005;5:73
[
16000172.001
]
[Cites]
J Biol Chem. 2005 Nov 4;280(44):36541-4
[
16115897.001
]
[Cites]
Eur J Immunol. 2005 Dec;35(12):3405-13
[
16224818.001
]
[Cites]
World J Gastroenterol. 2006 Jan 7;12(1):60-5
[
16440418.001
]
[Cites]
J Urol. 2006 Apr;175(4):1523-8
[
16516040.001
]
[Cites]
J Immunol. 2006 Dec 15;177(12):8730-9
[
17142775.001
]
[Cites]
Oncogene. 2007 May 14;26(22):3100-12
[
17496909.001
]
[Cites]
Mol Endocrinol. 2007 Jun;21(6):1267-80
[
17389748.001
]
[Cites]
Autoimmun Rev. 2007 Nov;7(1):8-11
[
17967718.001
]
[Cites]
Electrophoresis. 2007 Dec;28(23):4302-10
[
18041032.001
]
[Cites]
Intensive Care Med. 2008 Feb;34(2):361-7
[
17940748.001
]
[Cites]
Inflamm Res. 2008 Feb;57(2):45-50
[
18288453.001
]
[Cites]
J Cell Physiol. 2008 Jun;215(3):665-75
[
18064633.001
]
[Cites]
Oncology. 2008;75(3-4):127-33
[
18791328.001
]
[Cites]
J Clin Invest. 2008 Nov;118(11):3533-6
[
18982159.001
]
[Cites]
J Cell Biochem. 2008 Dec 1;105(5):1279-88
[
18821572.001
]
[Cites]
Mol Cell Biol. 2009 Apr;29(7):1922-32
[
19188446.001
]
[Cites]
Blood. 2000 Feb 15;95(4):1117-23
[
10666179.001
]
(PMID = 19762145.001).
[ISSN]
1872-7980
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / R21 DK075059; United States / NIAID NIH HHS / AI / R01 AI042310-06; United States / NIDDK NIH HHS / DK / DK075059; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NIDDK NIH HHS / DK / DK075059-02; United States / NIDDK NIH HHS / DK / R21 DK075059-02
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Multiprotein Complexes; 9000-94-6 / Antithrombin III
[Other-IDs]
NLM/ NIHMS146096; NLM/ PMC2832085
7.
Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE:
Anal carcinoma in mid-Norway 1970-2000.
Acta Oncol
; 2007;46(7):1019-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal carcinoma
in mid-Norway 1970-2000.
The treatment of
anal carcinoma
changed from surgery to chemoradiotherapy 20-25 years ago.
The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for
anal carcinoma
.
The study includes all 111 patients with
anal carcinoma
diagnosed between 1970 and 2000 in mid-Norway.
Stage
, age and treatment were all significant indicators of survival in uni- and multivariable analysis.
Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the
anal
sphincter.
The change of strategy for
anal
cancer
treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
[MeSH-major]
Anus
Neoplasms / therapy.
Carcinoma
/ therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17882558.001).
[ISSN]
0284-186X
[Journal-full-title]
Acta oncologica (Stockholm, Sweden)
[ISO-abbreviation]
Acta Oncol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Norway
8.
Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS:
Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.
Proteome Sci
; 2010;8:58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Patients with ovarian
carcinoma
excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.
BACKGROUND: Diagnosis of ovarian
carcinoma
is in urgent need for new complementary biomarkers for early
stage
detection.
Proteins that are aberrantly excreted in the urine
of cancer
patients are excellent biomarker candidates for development of new noninvasive protocol for early diagnosis and screening purposes.
In the present study, urine samples from patients with ovarian
carcinoma
were analysed by two-dimensional gel electrophoresis and the profiles generated were compared to those similarly obtained from age-matched
cancer
negative women.
RESULTS: Significant reduced levels of CD59, kininogen-1 and a 39 kDa fragment of inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), and enhanced excretion of a 19 kDa fragment of albumin, were detected in the urine of patients with ovarian
carcinoma
compared to the control subjects.
CONCLUSION: CD59, kininogen-1 and fragments of ITIH4 and albumin may be used as complementary biomarkers in the development of new noninvasive protocols for diagnosis and screening of ovarian
carcinoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21083881.001).
[ISSN]
1477-5956
[Journal-full-title]
Proteome science
[ISO-abbreviation]
Proteome Sci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2998473
9.
Jelski W, Mroczko B, Szmitkowski M:
The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
Dig Dis Sci
; 2010 Oct;55(10):2953-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal
cancer
patients.
BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal
cancer
tissue than in healthy mucosa.
The activity of these enzymes in
cancer
cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal
cancer
.
AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal
cancer
.
METHODS: Serum samples were taken from 182 patients with colorectal
cancer
before treatment and from 160 control subjects.
RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal
cancer
patients compared to the control.
The sensitivity and specificity of ADH I increased with the
stage
of the
carcinoma
.
CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal
cancer
.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
FEBS Lett. 1989 Oct 23;257(1):105-9
[
2806555.001
]
[Cites]
Clin Chem. 1993 Nov;39(11 Pt 1):2298-304
[
8222224.001
]
[Cites]
Clin Exp Med. 2006 Jun;6(2):89-93
[
16820997.001
]
[Cites]
Anal Biochem. 1989 Apr;178(1):57-62
[
2729580.001
]
[Cites]
Dig Dis Sci. 2004 Jun;49(6):977-81
[
15309886.001
]
[Cites]
Clin Exp Med. 2007 Dec;7(4):154-7
[
18188528.001
]
[Cites]
Anal Biochem. 1979 Oct 15;99(1):65-71
[
231394.001
]
[Cites]
Dig Dis Sci. 2005 Jun;50(6):1019-24
[
15986847.001
]
[Cites]
Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810
[
12418049.001
]
[Cites]
Digestion. 1996;57(2):105-8
[
8785998.001
]
[Cites]
Clin Chem Lab Med. 2008;46(10):1423-8
[
18844497.001
]
[Cites]
Clin Chim Acta. 2006 Sep;371(1-2):143-7
[
16603145.001
]
[Cites]
Clin Chim Acta. 2007 May 1;380(1-2):208-12
[
17368603.001
]
[Cites]
Alcohol Clin Exp Res. 1996 May;20(3):551-5
[
8727253.001
]
[Cites]
Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76
[
8986205.001
]
[Cites]
Int J Colorectal Dis. 2007 Jan;22(1):33-8
[
16520929.001
]
[Cites]
Clin Chem Lab Med. 2003 May;41(5):646-51
[
12812262.001
]
[Cites]
BMJ. 2000 Feb 12;320(7232):424-7
[
10669448.001
]
(PMID = 20069455.001).
[ISSN]
1573-2568
[Journal-full-title]
Digestive diseases and sciences
[ISO-abbreviation]
Dig. Dis. Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
10.
Baek WS, Kubba SV:
Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary.
Gynecol Oncol
; 2008 Dec;111(3):544-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CASE: A 66-year-old female with
stage
IV ovarian papillary serous cystadenocarcinoma presented with perianal numbness and sphincter dysfunction.
On exam she had decreased
anal
tone with saddle anesthesia.
CONCLUSION: Ovarian
cancer
metastasizng to the cauda equina should be highly suspected based on the clinical presentation alone, even with unremarkable imaging studies.
[MeSH-major]
Carcinoma
, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Meningeal Carcinomatosis / pathology. Ovarian Neoplasms / pathology. Polyradiculopathy / pathology
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18433846.001).
[ISSN]
1095-6859
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
11.
Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F:
Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula.
Suppl Tumori
; 2005 May-Jun;4(3):S31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal carcinoma
occurring in Crohn's disease patients with chronic
anal
fistula.
This paper reports six patients with perianal Crohn's disease (CD), who developed
anal
cancer
in chronic
anal
fistulas.
Tumors have been often diagnosed at an advanced
stage
and had a worse prognosis than cancers arising in the general population as tumor symptoms may mimic symptoms of CD, resulting in delay in diagnosis.
Patients with perianal CD should undergo a careful surveillance program for ano-rectal
carcinoma
, including routine biopsy of any suspected lesion.
[MeSH-major]
Anus
Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / complications
Genetic Alliance.
consumer health - Crohn Disease
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Crohn's Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16437885.001).
[ISSN]
2283-5423
[Journal-full-title]
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
[ISO-abbreviation]
Suppl Tumori
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
12.
Amano M, Yamaguchi M, Takegawa Y, Yamashita T, Terashima M, Furukawa J, Miura Y, Shinohara Y, Iwasaki N, Minami A, Nishimura S:
Threshold in stage-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation.
Mol Cell Proteomics
; 2010 Mar;9(3):523-37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Threshold in
stage
-specific embryonic glycotypes uncovered by a full portrait of dynamic N-glycan expression during cell differentiation.
We demonstrated that processes of dynamic cellular differentiation of mouse embryonic
carcinoma
cells, P19CL6 and P19C6, and mouse embryonic stem cells into cardiomyocytes or neural cells can be monitored and characterized quantitatively by profiling entire N-glycan structures of total cell glycoproteins.
[MeSH-major]
Cell Differentiation. Embryonal
Carcinoma
Stem Cells / chemistry. Embryonic Stem Cells / chemistry. Glycoproteins / analysis. Myocytes, Cardiac / chemistry. Neurons / chemistry. Polysaccharides / analysis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochem Biophys Res Commun. 2001 Jun 29;284(5):1098-103
[
11414696.001
]
[Cites]
Angew Chem Int Ed Engl. 2008;47(31):5718-38
[
18624353.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Apr 26;293(1):167-73
[
12054580.001
]
[Cites]
Biochim Biophys Acta. 2002 Dec 19;1573(3):363-8
[
12417419.001
]
[Cites]
Annu Rev Biochem. 2004;73:491-537
[
15189151.001
]
[Cites]
Curr Biol. 2004 Sep 7;14(17):R691-2
[
15341754.001
]
[Cites]
Glycoconj J. 2004;21(1-2):41-5
[
15467397.001
]
[Cites]
Proc Natl Acad Sci U S A. 1978 Nov;75(11):5565-9
[
281705.001
]
[Cites]
Cell. 1979 Sep;18(1):217-27
[
509524.001
]
[Cites]
Nature. 1982 Sep 9;299(5879):165-7
[
7110336.001
]
[Cites]
Mol Cell Biol. 1983 Dec;3(12):2280-6
[
6656767.001
]
[Cites]
EMBO J. 1983;2(12):2355-61
[
6141938.001
]
[Cites]
J Biol Chem. 1989 Jun 5;264(16):9476-84
[
2470757.001
]
[Cites]
Glycobiology. 1993 Apr;3(2):97-130
[
8490246.001
]
[Cites]
Anal Biochem. 1993 Oct;214(1):70-6
[
8250257.001
]
[Cites]
J Biochem. 1993 Sep;114(3):334-8
[
8282722.001
]
[Cites]
Cell Struct Funct. 1996 Apr;21(2):101-10
[
8790939.001
]
[Cites]
Glycobiology. 1997 Feb;7(1):45-56
[
9061364.001
]
[Cites]
Glycobiology. 1999 Aug;9(8):823-31
[
10406848.001
]
[Cites]
Angew Chem Int Ed Engl. 2004 Dec 17;44(1):91-6
[
15599899.001
]
[Cites]
Nat Med. 2005 Feb;11(2):228-32
[
15685172.001
]
[Cites]
Proteomics. 2005 Apr;5(6):1656-68
[
15789344.001
]
[Cites]
Stem Cells. 2006 Jan;24(1):145-50
[
16253979.001
]
[Cites]
Glycobiology. 2006 Mar;16(3):244-57
[
16321922.001
]
[Cites]
Cell. 2006 Sep 8;126(5):855-67
[
16959566.001
]
[Cites]
Cell Biol Int. 2006 Oct;30(10):800-7
[
16877013.001
]
[Cites]
Proteomics. 2006 Oct;6(20):5650-61
[
16972299.001
]
[Cites]
Mol Cell Proteomics. 2006 Nov;5(11):2146-57
[
16899540.001
]
[Cites]
Cell. 2007 Apr 6;129(1):123-34
[
17418791.001
]
[Cites]
Nature. 2007 Apr 26;446(7139):1023-9
[
17460663.001
]
[Cites]
Proteomics. 2007 Mar;7(6):910-20
[
17370269.001
]
[Cites]
Curr Opin Chem Biol. 2007 Jun;11(3):300-5
[
17500024.001
]
[Cites]
J Cell Biochem. 2007 Sep 1;102(1):149-60
[
17520663.001
]
[Cites]
Curr Opin Chem Biol. 2007 Aug;11(4):399-404
[
17646122.001
]
[Cites]
Curr Opin Chem Biol. 2007 Aug;11(4):373-80
[
17681848.001
]
[Cites]
Cell. 2007 Nov 30;131(5):861-72
[
18035408.001
]
[Cites]
J Proteome Res. 2008 Jan;7(1):328-38
[
18034457.001
]
[Cites]
Proteomics. 2008 Jan;8(2):264-78
[
18203276.001
]
[Cites]
Mol Cell Proteomics. 2008 Feb;7(2):370-7
[
17986439.001
]
[Cites]
Anal Chem. 2008 Feb 15;80(4):1094-101
[
18205388.001
]
[Cites]
Science. 2002 Jan 4;295(5552):124-7
[
11778047.001
]
(PMID = 20008832.001).
[ISSN]
1535-9484
[Journal-full-title]
Molecular & cellular proteomics : MCP
[ISO-abbreviation]
Mol. Cell Proteomics
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Glycoproteins; 0 / Polysaccharides
[Other-IDs]
NLM/ PMC2849713
13.
Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA:
SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
BMC Cancer
; 2010;10:300
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal
carcinoma
of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
BACKGROUND: The development and progression of colorectal
cancer
has been extensively studied and the genes responsible have been well characterized.
METHODS: We examined the paired tumor and normal tissue specimens of 86 CRC patients for the occurrence of aberrations in MCR region of SMAD4 and exon
1 of
KRAS by PCR-SSCP and/or PCR-Direct sequencing.
CONCLUSION: Our study suggests that SMAD4 gene aberrations are the common event in CRC development but play a differential role in the progression of CRC in higher tumor grade (C+D) and its association with the KRAS mutant status suggest that these two molecules together are responsible for the progression of the tumor to higher/advanced
stage
.
[MeSH-major]
Adenocarcinoma / genetics.
Carcinoma
, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Science. 1990 Jan 5;247(4938):49-56
[
2294591.001
]
[Cites]
Mol Cell Biochem. 2009 Dec;332(1-2):51-8
[
19513816.001
]
[Cites]
Carcinogenesis. 1992 Aug;13(8):1331-5
[
1499084.001
]
[Cites]
Curr Opin Oncol. 1993 Jan;5(1):123-9
[
8427884.001
]
[Cites]
Science. 1996 Jan 19;271(5247):350-3
[
8553070.001
]
[Cites]
Cancer Res. 1996 Jun 1;56(11):2527-30
[
8653691.001
]
[Cites]
Nat Genet. 1996 Jul;13(3):347-9
[
8673135.001
]
[Cites]
Genes Dev. 2006 Nov 15;20(22):3130-46
[
17114584.001
]
[Cites]
Biochim Biophys Acta. 2007 Jan;1775(1):21-62
[
16904831.001
]
[Cites]
Cancer Cell. 2007 Mar;11(3):229-43
[
17349581.001
]
[Cites]
Nat Rev Cancer. 2007 Apr;7(4):295-308
[
17384584.001
]
[Cites]
Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8
[
8741784.001
]
[Cites]
Cancer Res. 1997 Jul 1;57(13):2578-80
[
9205057.001
]
[Cites]
J Pathol. 1998 Jun;185(2):130-8
[
9713338.001
]
[Cites]
Annu Rev Biochem. 1998;67:753-91
[
9759503.001
]
[Cites]
Cancer Res. 1998 Nov 15;58(22):5248-57
[
9823339.001
]
[Cites]
Oncogene. 1999 Mar 18;18(11):2033-7
[
10208426.001
]
[Cites]
Oncogene. 1999 May 20;18(20):3098-103
[
10340381.001
]
[Cites]
Mutat Res. 1999 Aug;406(2-4):71-7
[
10479724.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):2078-93
[
15774796.001
]
[Cites]
Int J Cancer. 2005 Aug 10;116(1):62-8
[
15761872.001
]
[Cites]
Am Surg. 2005 Apr;71(4):336-43
[
15943410.001
]
[Cites]
Gut. 2005 Sep;54(9):1283-6
[
15843421.001
]
[Cites]
Oncogene. 2005 Aug 29;24(37):5742-50
[
16123807.001
]
[Cites]
Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40
[
16289860.001
]
[Cites]
World J Gastroenterol. 2006 Jul 7;12(25):4033-7
[
16810754.001
]
[Cites]
Int J Biol Sci. 2010;6(1):1-8
[
20087440.001
]
[Cites]
Gastroenterology. 2010 Mar;138(3):969-80.e1-3
[
19909744.001
]
[Cites]
Curr Opin Cell Biol. 2000 Apr;12(2):235-43
[
10712925.001
]
[Cites]
N Engl J Med. 2000 May 4;342(18):1350-8
[
10793168.001
]
[Cites]
Bioessays. 2001 Mar;23(3):223-32
[
11223879.001
]
[Cites]
Ann Agric Environ Med. 2001;8(1):1-5
[
11426918.001
]
[Cites]
Genome Biol. 2001;2(8):REVIEWS3010
[
11532220.001
]
[Cites]
Am J Pathol. 2001 Oct;159(4):1293-300
[
11583957.001
]
[Cites]
J Cell Biol. 2002 Jan 21;156(2):299-313
[
11790801.001
]
[Cites]
J Expo Anal Environ Epidemiol. 2002 Sep;12(5):373-80
[
12198585.001
]
[Cites]
Ann Intern Med. 2002 Oct 1;137(7):603-12
[
12353948.001
]
[Cites]
Br Med Bull. 2002;64:1-25
[
12421722.001
]
[Cites]
Int J Cancer. 2003 Nov 10;107(3):387-93
[
14506738.001
]
[Cites]
Nature. 2003 Oct 9;425(6958):577-84
[
14534577.001
]
[Cites]
Clin Cancer Res. 2004 Mar 1;10(5):1597-604
[
15014009.001
]
[Cites]
Exp Oncol. 2004 Jun;26(2):98-105
[
15273660.001
]
[Cites]
Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85
[
15358723.001
]
[Cites]
N Engl J Med. 1988 Sep 1;319(9):525-32
[
2841597.001
]
[Cites]
Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003
[
3056609.001
]
[Cites]
Int J Cancer. 2007 Jul 15;121(2):339-46
[
17390374.001
]
[Cites]
J Biol Chem. 2009 Jan 2;284(1):245-53
[
19010789.001
]
[Cites]
Mutat Res. 2009 May 31;676(1-2):5-10
[
19486858.001
]
[Cites]
Indian J Cancer. 2009 Jul-Sep;46(3):219-25
[
19574674.001
]
[Cites]
Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52
[
19794270.001
]
[Cites]
Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23
[
19838011.001
]
[Cites]
Indian J Pathol Microbiol. 1990 Apr;33(2):118-23
[
2391141.001
]
(PMID = 20565773.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 3.6.5.2 / ras Proteins
[Other-IDs]
NLM/ PMC2927996
14.
Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW:
Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
Ann Surg Oncol
; 2007 Feb;14(2):478-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Results of surgical salvage after failed chemoradiation therapy for epidermoid
carcinoma
of the
anal
canal
.
BACKGROUND: The standard treatment for epidermoid
carcinoma
of the
anal
canal
consists of combined radiation and chemotherapy.
Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T)
stage
, and margin status of resection.
CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid
carcinoma
of the
anal
canal
can be achieved in the majority of patients.
[MeSH-major]
Anus
Neoplasms / therapy.
Carcinoma
, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery
Genetic Alliance.
consumer health - Epidermoid Carcinoma
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17103253.001).
[ISSN]
1068-9265
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
15.
Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM:
Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.
J Clin Invest
; 2005 Feb;115(2):339-47
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon
carcinoma
.
We used a spheroid model of colon
carcinoma
to analyze integrin dynamics as a function of the epithelial-mesenchymal transition (EMT), a process that provides a paradigm for understanding how
carcinoma
cells acquire a more aggressive phenotype.
This integrin enhances the tumorigenic properties of colon
carcinoma
, including activation of autocrine TGF-beta and migration on interstitial fibronectin.
Elevated receptor expression did not simply reflect increasing tumor
stage
, since log-rank analysis showed a more significant impact on the survival of patients with early-
stage
, as opposed to late-
stage
, disease.
These findings define the alphavbeta6 integrin as an important risk factor for early-
stage
disease and a novel therapeutic candidate for colorectal
cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Invest. 1991 Jan;87(1):1-5
[
1985087.001
]
[Cites]
Anal Biochem. 1994 Feb 1;216(2):276-84
[
8179182.001
]
[Cites]
J Cell Biol. 1995 May;129(3):853-65
[
7537276.001
]
[Cites]
J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51
[
7673344.001
]
[Cites]
Cancer Surv. 1995;24:67-79
[
7553663.001
]
[Cites]
Acta Anat (Basel). 1995;154(1):8-20
[
8714286.001
]
[Cites]
Mol Cell Biol. 1996 Sep;16(9):5091-106
[
8756667.001
]
[Cites]
Genes Dev. 1996 Oct 1;10(19):2462-77
[
8843198.001
]
[Cites]
Am J Physiol. 1997 Jul;273(1 Pt 1):L256-63
[
9252563.001
]
[Cites]
Curr Biol. 1998 Nov 19;8(23):1243-52
[
9822576.001
]
[Cites]
Cell. 1999 Feb 5;96(3):319-28
[
10025398.001
]
[Cites]
Circ Res. 1999 May 28;84(10):1177-85
[
10347092.001
]
[Cites]
J Biol Chem. 2004 Apr 23;279(17):17875-87
[
14960589.001
]
[Cites]
Br J Cancer. 2000 Apr;82(8):1433-40
[
10780523.001
]
[Cites]
Genes Dev. 2000 Oct 15;14(20):2610-22
[
11040215.001
]
[Cites]
Mol Biol Cell. 2001 Jan;12(1):27-36
[
11160820.001
]
[Cites]
J Clin Invest. 2001 Jun;107(12):1537-44
[
11413161.001
]
[Cites]
Exp Mol Pathol. 2001 Jun;70(3):255-64
[
11418004.001
]
[Cites]
Bioessays. 2001 Oct;23(10):912-23
[
11598958.001
]
[Cites]
Oral Oncol. 2002 Jun;38(4):332-6
[
12076695.001
]
[Cites]
Nat Rev Cancer. 2002 Jun;2(6):442-54
[
12189386.001
]
[Cites]
Gene. 2003 Jan 16;303:11-34
[
12559563.001
]
[Cites]
Nature. 2003 Mar 13;422(6928):169-73
[
12634787.001
]
[Cites]
Mol Biol Cell. 2003 May;14(5):1790-800
[
12802055.001
]
[Cites]
Curr Biol. 2003 Sep 30;13(19):1721-7
[
14521839.001
]
[Cites]
Curr Opin Cell Biol. 2003 Dec;15(6):740-6
[
14644200.001
]
[Cites]
Cancer Res. 1987 May 15;47(10):2683-9
[
3567898.001
]
[Cites]
Cell. 1992 Apr 3;69(1):11-25
[
1555235.001
]
[Cites]
J Biol Chem. 1992 Mar 25;267(9):5790-6
[
1532572.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8
[
7694284.001
]
[Cites]
J Histochem Cytochem. 1993 Oct;41(10):1521-7
[
8245410.001
]
[Cites]
J Cell Biol. 1994 Apr;125(2):403-15
[
8163556.001
]
[Cites]
Nucleic Acids Res. 1992 Feb 25;20(4):920
[
1311835.001
]
(PMID = 15668738.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / P30 DK034854; United States / NIDDK NIH HHS / DK / DK34854; United States / NCI NIH HHS / CA / CA107548; United States / NCI NIH HHS / CA / R01 CA107548; United States / NCI NIH HHS / CA / CA 80789; United States / NCI NIH HHS / CA / R01 CA080789
[Publication-type]
Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Integrin alpha5; 0 / Integrin beta Chains; 0 / Transforming Growth Factor beta; 0 / integrin beta6
[Other-IDs]
NLM/ PMC544606
16.
Zuo ZG, Song HY, Li J, Xu C, Zhou ZH, Ni SC, Chen SQ:
[Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma].
Zhonghua Zhong Liu Za Zhi
; 2009 Dec;31(12):941-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical application of intersphincteric resection in the
anal
-preserving operation for ultra-low rectal
carcinoma
].
OBJECTIVE: To investigate the clinical application of intersphincter resection (ISR) combined with total mesorectal excision (TME) and colon-
anal
anastomosis in the treatment for ultra-low rectal
carcinoma
.
METHODS: To review and analyze retrospectively the data of 34 patients with ultra-low rectal
carcinoma
(without external
anal
sphincter involvement) who received treatment of ISR, TME and colon-
anal
anastomosis.
Reconstruction of digestive tract was done by manual colon-
anal
anastomosis.
The pathological types were as follows: 28 cases of adenocarcinoma (11 were well differentiated, 17 moderately differentiated), 1 case of papillary
carcinoma
and 5 cases of villous adenoma with malignant change.
The postoperative pathological stages were: Dukes
stage
A in 28 cases,
stage
B in 1 and
stage
C in 5 cases.
CONCLUSION: With strictly grasping indications, radical resection can be attained and
anal
sphincter preserved by ISR combined with TME and colon-
anal
anastomosis.
[MeSH-major]
Adenocarcinoma / surgery.
Anal
Canal
/ surgery. Rectal Neoplasms / surgery. Rectum / surgery
[MeSH-minor]
Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical.
Carcinoma
, Papillary / pathology.
Carcinoma
, Papillary / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Surgical Wound Dehiscence / etiology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20193339.001).
[ISSN]
0253-3766
[Journal-full-title]
Zhonghua zhong liu za zhi [Chinese journal of oncology]
[ISO-abbreviation]
Zhonghua Zhong Liu Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Evaluation Studies; Journal Article
[Publication-country]
China
17.
Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK:
Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
Dis Colon Rectum
; 2008 Feb;51(2):147-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Squamous-cell
carcinoma
of the
anal
canal
: predictors of treatment outcome.
PURPOSE: The incidence of
anal
canal
squamous-cell
carcinoma
is increasing.
METHODS: Using one database, we identified 131 Stages I-III patients treated for primary
anal
canal
squamous-cell
carcinoma
at our institution from December 1986 to August 2006, with minimum six-month follow-up.
RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were
Stage
II, and 11 (8 percent) were HIV-positive.
Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent)
Stage
III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
Many (44 percent Stages I/II, 48.9 percent
Stage
III) required dose adjustments.
Bivariate analyses demonstrated that T
stage
(P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
On multivariate analyses, disease
stage
(P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
[MeSH-major]
Anus
Neoplasms / therapy.
Carcinoma
, Squamous Cell / therapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Dis Colon Rectum. 2008 May;51(5):620
(PMID = 18180997.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
18.
Chiappa A, Biffi R, Zbar AP, Luca F, Crotti C, Bertani E, Biella F, Zampino G, Orecchia R, Fazio N, Venturino M, Crosta C, Pruneri GC, Grassi C, Andreoni B:
Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003.
Int J Colorectal Dis
; 2005 May;20(3):221-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Results of treatment of distal rectal
carcinoma
since the introduction of total mesorectal excision: a single unit experience, 1994-2003.
BACKGROUND AND AIMS: This study reviewed the results of surgery for distal rectal
cancer
(where the tumour was within 6 cm of the
anal
verge) following the introduction of total mesorectal excision for rectal
cancer
in one institution.
PATIENTS AND METHODS: One hundred and fifty-three patients who had undergone elective curative surgical resection of rectal
cancer
within 6 cm of the
anal
verge were included.
On multivariate analysis type of surgery (P=0.025) and tumour
stage
(P=0.043), were associated with local recurrence, but only
stage
was a significant prognosticator of overall survival (P=0.0006).
CONCLUSION: With the practice of total mesorectal excision, APR was still necessary in 40% of patients with rectal
cancer
within 6 cm of the
anal
verge.
[MeSH-major]
Carcinoma
/ surgery. Digestive System Surgical Procedures / methods. Postoperative Care / methods. Rectal Neoplasms / surgery
MedlinePlus Health Information.
consumer health - After Surgery
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
World J Surg. 2002 Oct;26(10):1272-6
[
12205546.001
]
[Cites]
Br J Surg. 1995 Aug;82(8):1031-3
[
7648142.001
]
[Cites]
Dis Colon Rectum. 1997 Jul;40(7):747-51
[
9221846.001
]
[Cites]
Tech Coloproctol. 2001 Aug;5(2):97-102
[
11862566.001
]
[Cites]
Arch Surg. 1998 Aug;133(8):894-9
[
9711965.001
]
[Cites]
Dis Colon Rectum. 1990 Feb;33(2):117-21
[
2298097.001
]
[Cites]
Br J Surg. 1996 Mar;83(3):375-9
[
8665198.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Br J Surg. 1985 Jan;72(1):34-7
[
3967128.001
]
[Cites]
Br J Surg. 2002 Sep;89(9):1142-9
[
12190680.001
]
[Cites]
Lancet. 2000 Jul 8;356(9224):93-6
[
10963244.001
]
[Cites]
Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6
[
11330574.001
]
[Cites]
N Engl J Med. 1985 Jun 20;312(25):1604-8
[
4000199.001
]
[Cites]
Dis Colon Rectum. 2001 Jul;44(7):947-54
[
11496074.001
]
[Cites]
Dis Colon Rectum. 1997 Jan;40(1):117
[
9102254.001
]
[Cites]
Dis Colon Rectum. 1995 Aug;38(8):799-802
[
7543403.001
]
[Cites]
Dis Colon Rectum. 1991 Apr;34(4):317-22
[
2007349.001
]
[Cites]
Br J Surg. 2003 Aug;90(8):974-80
[
12905551.001
]
[Cites]
Aust N Z J Surg. 2000 Oct;70(10 ):704-9
[
11021483.001
]
[Cites]
Br J Surg. 2001 Nov;88(11):1501-5
[
11683749.001
]
[Cites]
Br J Surg. 1999 Sep;86(9):1164-70
[
10504371.001
]
[Cites]
Eur J Surg Oncol. 2000 Dec;26(8):751-7
[
11087640.001
]
[Cites]
Eur J Surg. 1996 Aug;162(8):643-8
[
8891623.001
]
[Cites]
Br J Surg. 1984 Sep;71(9):659-63
[
6478151.001
]
[Cites]
Dis Colon Rectum. 2000 Dec;43(12):1710-2
[
11156455.001
]
[Cites]
Surgery. 1998 Oct;124(4):612-7; discussion 617-8
[
9780979.001
]
[Cites]
Cancer. 1988 Apr 1;61(7):1408-16
[
3345493.001
]
[Cites]
Dis Colon Rectum. 2002 Jul;45(7):857-66
[
12130870.001
]
[Cites]
Eur J Surg Oncol. 2003 Apr;29(3):239-43
[
12657233.001
]
[Cites]
Ann Surg Oncol. 2003 Jan-Feb;10(1):72-9
[
12513964.001
]
[Cites]
Dis Colon Rectum. 1996 Mar;39(3):323-8
[
8603556.001
]
[Cites]
Dis Colon Rectum. 1992 Mar;35(3):238-41
[
1740068.001
]
[Cites]
Eur J Surg Oncol. 1995 Feb;21(1):11-5
[
7851543.001
]
[Cites]
Eur J Surg Oncol. 1995 Dec;21(6):640-3
[
8631412.001
]
[Cites]
Colorectal Dis. 2001 May;3(3):179-84
[
12790986.001
]
[Cites]
Dis Colon Rectum. 2002 Jul;45(7):895-903
[
12130878.001
]
[Cites]
Ann Surg. 1990 Jun;211(6):745-51; discussion 751-2
[
2357137.001
]
[Cites]
Dis Colon Rectum. 1998 Aug;41(8):979-83
[
9715152.001
]
[Cites]
Br J Surg. 2003 Oct;90(10):1261-6
[
14515297.001
]
[Cites]
Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5
[
12513965.001
]
[Cites]
Chir Ital. 2003 May-Jun;55(3):333-44
[
12872567.001
]
[Cites]
Br J Surg. 1999 Mar;86(3):379-84
[
10201783.001
]
[Cites]
Dis Colon Rectum. 2004 Jan;47(1):48-58
[
14719151.001
]
[Cites]
Br J Surg. 1998 Apr;85(4):526-9
[
9607540.001
]
(PMID = 15602647.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
19.
Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG:
[Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma].
Zhonghua Wei Chang Wai Ke Za Zhi
; 2009 Nov;12(6):569-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal
carcinoma
].
OBJECTIVE: To analyze the impact of meticulousness of pathologists on the lymph node harvest after radical resection of invasive rectal
carcinoma
.
METHODS: From January 2008 to May 2009, the clinical data of rectal
cancer
patients undergone operation were reviewed retrospectively.
After multidisciplinary cooperation on rectal
cancer
, a new rule was applied to request the pathologists to find no less than 15 nodes in single colorectal specimen from January 2009.
Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal
cancer
(familial adenomatous polyposis, synchronous colorectal
carcinoma
) and rectal
cancer
receiving neoadjuvant chemoradiation.
There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to
anal
verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM
stage
(P=0.167) between the two groups.
The good performance of pathologists could produce adequate number of lymph nodes for rectal
cancer
without neoadjuvant chemoradiation.
MedlinePlus Health Information.
consumer health - Biopsy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19921565.001).
[ISSN]
1671-0274
[Journal-full-title]
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
[ISO-abbreviation]
Zhonghua Wei Chang Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
20.
Matsopoulos GK, Mouravliansky NA, Asvestas PA, Delibasis KK, Kouloulias V:
Thoracic non-rigid registration combining self-organizing maps and radial basis functions.
Med Image Anal
; 2005 Jun;9(3):237-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
An automatic three-dimensional non-rigid registration scheme is proposed in this paper and applied to thoracic computed tomography (CT) data of patients with
stage
III non-small cell lung
cancer
(NSCLC).
[MeSH-major]
Carcinoma
, Non-Small-Cell Lung / radiography. Imaging, Three-Dimensional / methods. Lung Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Radiography, Thoracic / methods. Subtraction Technique
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15854844.001).
[ISSN]
1361-8415
[Journal-full-title]
Medical image analysis
[ISO-abbreviation]
Med Image Anal
[Language]
eng
[Publication-type]
Clinical Trial; Controlled Clinical Trial; Journal Article
[Publication-country]
England
21.
Hatfield P, Cooper R, Sebag-Montefiore D:
Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
Int J Radiat Oncol Biol Phys
; 2008 Feb 1;70(2):419-24
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Involved-field, low-dose chemoradiotherapy for early-
stage anal carcinoma
.
PURPOSE: To report the results of patients with early-
stage anal
cancer
treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
All were considered to have
Stage
N0 disease radiologically.
CONCLUSION: The results of our study have shown that for patients with
anal carcinoma
who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy
MedlinePlus Health Information.
consumer health - Anal Cancer
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17919842.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
22.
Courter LA, Luch A, Musafia-Jeknic T, Arlt VM, Fischer K, Bildfell R, Pereira C, Phillips DH, Poirier MC, Baird WM:
The influence of diesel exhaust on polycyclic aromatic hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo.
Cancer Lett
; 2008 Jun 28;265(1):135-47
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We evaluated the influence of diesel exhaust particulate matter on PAH-induced cytochrome P450 (CYP) activity, PAH-DNA adduct formation, expression of certain candidate genes and the frequency of tumor initiation in the two-
stage
Sencar mouse model.
The applied diesel particulate matter (SRM(1975)) altered the tumor initiating potency of DBP: a statistically significant decrease in overall tumor and
carcinoma
burden was observed following 25 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), compared with DBP exposure alone.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
12-O-TETRADECANOYLPHORBOL-13-ACETATE
.
Hazardous Substances Data Bank.
DIBENZO(A,L)PYRENE
.
Hazardous Substances Data Bank.
Benzo(a)pyrene
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Carcinogenesis. 1995 Sep;16(9):2083-9
[
7554058.001
]
[Cites]
Cancer Res. 1996 Jul 1;56(13):2979-84
[
8674051.001
]
[Cites]
Science. 1996 Oct 18;274(5286):430-2
[
8832894.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Jun 29;358(2):442-8
[
17490615.001
]
[Cites]
Mutat Res. 2007 Dec 1;625(1-2):72-82
[
17612574.001
]
[Cites]
Nat Protoc. 2007;2(11):2772-81
[
18007613.001
]
[Cites]
Chem Res Toxicol. 2007 Dec;20(12):1797-810
[
17944540.001
]
[Cites]
Carcinogenesis. 2000 Apr;21(4):653-61
[
10753200.001
]
[Cites]
N Engl J Med. 2000 Dec 14;343(24):1742-9
[
11114312.001
]
[Cites]
Hum Exp Toxicol. 2000 Oct;19(10):573-95
[
11211997.001
]
[Cites]
Environ Health Perspect. 2001 Jan;109(1):71-4
[
11171528.001
]
[Cites]
Cancer Res. 2001 Mar 15;61(6):2727-31
[
11289154.001
]
[Cites]
Carcinogenesis. 2001 Jul;22(7):1077-86
[
11408352.001
]
[Cites]
Histol Histopathol. 2001 Jul;16(3):861-8
[
11510978.001
]
[Cites]
Int J Cancer. 2001 Oct 1;94(1):121-7
[
11668486.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
JAMA. 2002 Mar 6;287(9):1132-41
[
11879110.001
]
[Cites]
Mutat Res. 2002 Mar 25;515(1-2):85-98
[
11909757.001
]
[Cites]
Chemosphere. 2002 Apr;47(1):57-64
[
11996136.001
]
[Cites]
Toxicol Sci. 2002 Jun;67(2):241-6
[
12011483.001
]
[Cites]
Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93
[
12223276.001
]
[Cites]
Chem Res Toxicol. 2002 Sep;15(9):1127-35
[
12230405.001
]
[Cites]
Carcinogenesis. 2002 Nov;23(11):1937-45
[
12419844.001
]
[Cites]
Environ Res. 2003 Jul;92(3):191-6
[
12804515.001
]
[Cites]
Cancer Sci. 2004 Jan;95(1):1-6
[
14720319.001
]
[Cites]
Glycoconj J. 2004;19(7-9):557-63
[
14758080.001
]
[Cites]
Toxicol In Vitro. 2004 Jun;18(3):377-91
[
15046786.001
]
[Cites]
Environ Mol Mutagen. 2004;44(2):99-107
[
15278913.001
]
[Cites]
J Invest Dermatol. 1974 Oct;63(4):343-9
[
4424714.001
]
[Cites]
Int J Environ Anal Chem. 1981;9(2):93-144
[
7012053.001
]
[Cites]
Carcinogenesis. 1982;3(4):371-5
[
6284398.001
]
[Cites]
Cancer Lett. 1984 Oct;24(3):327-33
[
6437667.001
]
[Cites]
Mol Pharmacol. 1997 Dec;52(6):974-82
[
9415707.001
]
[Cites]
Cancer Res. 1998 May 15;58(10):2070-5
[
9605744.001
]
[Cites]
Chem Res Toxicol. 1998 Jun;11(6):686-95
[
9625737.001
]
[Cites]
J Investig Dermatol Symp Proc. 1996 Apr;1(2):151-6
[
9627710.001
]
[Cites]
Mutat Res. 1999 Mar 8;424(1-2):155-66
[
10064858.001
]
[Cites]
Mutagenesis. 1999 May;14(3):301-15
[
10374998.001
]
[Cites]
Toxicol Appl Pharmacol. 2004 Dec 1;201(2):178-85
[
15541757.001
]
[Cites]
Chem Res Toxicol. 2004 Dec;17(12):1667-74
[
15606143.001
]
[Cites]
Chem Res Toxicol. 2005 Feb;18(2):224-31
[
15720126.001
]
[Cites]
Cancer Res. 2005 Feb 15;65(4):1251-8
[
15735009.001
]
[Cites]
Crit Rev Toxicol. 2005 Jun;35(5):379-411
[
16097136.001
]
[Cites]
Curr Dir Autoimmun. 2006;9:1-17
[
16394652.001
]
[Cites]
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):845-53
[
16467098.001
]
[Cites]
Chem Res Toxicol. 2006 Feb;19(2):288-94
[
16485905.001
]
[Cites]
Toxicol Lett. 2006 Aug 20;165(2):182-94
[
16713138.001
]
[Cites]
BMC Genomics. 2006;7:260
[
17042939.001
]
[Cites]
Ann N Y Acad Sci. 2006 Sep;1076:253-65
[
17119207.001
]
[Cites]
Toxicol Sci. 2007 Jan;95(1):63-73
[
17060372.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 2007;47:263-92
[
16970545.001
]
[Cites]
Mutat Res. 2007 Feb 3;615(1-2):87-97
[
17141280.001
]
[Cites]
Int J Cancer. 2007 Mar 15;120(6):1161-8
[
17187366.001
]
[Cites]
Toxicology. 2007 Mar 7;231(2-3):159-74
[
17240030.001
]
[Cites]
Chem Res Toxicol. 2007 Mar;20(3):489-96
[
17291012.001
]
[Cites]
Cancer Res. 1987 Jul 15;47(14):3701-6
[
3109730.001
]
[Cites]
Sci Total Environ. 1987 Oct;66:95-114
[
3317821.001
]
[Cites]
Chem Biol Interact. 1988;68(1-2):127-36
[
3203403.001
]
[Cites]
Toxicology. 1990 Jan-Feb;60(1-2):127-35
[
1690463.001
]
[Cites]
Carcinogenesis. 1990 Sep;11(9):1611-9
[
2401051.001
]
[Cites]
Endocrinology. 1991 Aug;129(2):970-82
[
1649753.001
]
[Cites]
Carcinogenesis. 1991 Oct;12(10):1939-44
[
1934274.001
]
[Cites]
Carcinogenesis. 1992 Jul;13(7):1053-74
[
1638670.001
]
[Cites]
Carcinogenesis. 1993 May;14(5):875-8
[
8504480.001
]
[Cites]
N Engl J Med. 1993 Dec 9;329(24):1753-9
[
8179653.001
]
[Cites]
Environ Health Perspect. 1993 Dec;101 Suppl 4:155-65
[
7515806.001
]
[Cites]
Mol Carcinog. 1994 Jul;10(3):159-68
[
8043197.001
]
(PMID = 18353537.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
ENG
[Grant]
United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / R01 CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825-19; United States / NCI NIH HHS / CA / CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825; United States / NCI NIH HHS / CA / CA028825-19; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / R01 CA028825-23; United States / NCI NIH HHS / CA / CA028825-22; United States / NCI NIH HHS / CA / CA28825; United States / NCI NIH HHS / CA / CA028825-20; United States / NCI NIH HHS / CA / R01 CA028825-20; United States / NCI NIH HHS / CA / CA028825-24; United States / NCI NIH HHS / CA / R01 CA028825-22; United States / NIEHS NIH HHS / ES / T32 ES007060; United States / NCI NIH HHS / CA / R01 CA028825-24; United States / NIEHS NIH HHS / ES / P30 ES000210; United States / NCI NIH HHS / CA / CA028825-23
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Benzopyrenes; 0 / Carcinogens; 0 / DNA Adducts; 0 / Particulate Matter; 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Vehicle Emissions; 0 / polycyclic aromatic hydrocarbons-DNA adduct; 191-30-0 / dibenzo(a,l)pyrene; 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; NI40JAQ945 / Tetradecanoylphorbol Acetate
[Other-IDs]
NLM/ NIHMS53855; NLM/ PMC2519885
23.
Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H:
[High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review].
Dtsch Med Wochenschr
; 2006 Aug 25;131(34-35):1849-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The data were collected on all AIDS- and not-AIDS-defined haematological malignancies and all AIDS- and not-AIDS-defined solid malignant tumors in HIV-positive patients, as well as on time of diagnosis of the malignancy, tumor
stage
, tumor treatment and response to treatment.
Of the 200 (52.6%) not-AIDS-defined malignant tumors 133 were 133 solid tumors, 40 of them
anal carcinoma
(20% of all not-AIDS-defined malignancies) and 67 haematological malignancies, 22 of these Hodgkin's lymphoma (11.0% of all not-AIDS-defined malignancies).
The incidence of
anal carcinoma
is estimated to be 34 (95% CI 24-470) per 100 000 patient-years, that of Hodgkin's lymphoma 19 (95% CI 12-28) per 100 000 patient-years.
Of special note is the high incidence of
anal carcinoma
and Hodgkin's lymphoma, compared with their incidence among the entire German population.
[MeSH-major]
Anus
Neoplasms / epidemiology. HIV Infections / complications. Hodgkin Disease / epidemiology. Neoplasms / epidemiology. Neoplasms / virology
[MeSH-minor]
Carcinoma
/ epidemiology. Female. Germany / epidemiology. Humans. Incidence. Male. Retrospective Studies. Sex Factors. Surveys and Questionnaires
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16915544.001).
[ISSN]
0012-0472
[Journal-full-title]
Deutsche medizinische Wochenschrift (1946)
[ISO-abbreviation]
Dtsch. Med. Wochenschr.
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
24.
Helpap B, Egevad L:
Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
Anal Quant Cytol Histol
; 2008 Jun;30(3):133-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Correlation of modified Gleason grading of prostate
carcinoma
with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
STUDY DESIGN: A total of 828 consecutive needle biopsy specimens of prostate
carcinoma
were collected from the years 1995 and 2000 (graded with conventional Gleason grading) and 2006 and 2007 (graded with modified Gleason grading).
RESULTS: Both conventional and modified Gleason grading correlated with age, serum PSA, percent positive biopsies and percent
cancer
length.
Serum PSA and percent positive cores were lower than in the 1995 and 2000 group, indicating a
stage
shift downward, but the Gleason scores were nevertheless higher.
CONCLUSION: Conventional and modified Gleason grading both correlated with age, serum PSA and
cancer
involvement in needle biopsies.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer Screening
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18630837.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
25.
Nair KS, Naidoo R, Chetty R:
Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.
J Clin Pathol
; 2005 Apr;58(4):343-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of cell adhesion molecules in oesophageal
carcinoma
and its prognostic value.
Oesophageal
carcinoma
remains a disease of poor prognosis.
Surgical cure rates are compromised by the fact that most patients are diagnosed at a late
stage
of disease because of the delayed onset of symptoms, by which time metastases and organ infiltration may have already occurred.
This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in squamous cell
carcinoma
and adenocarcinoma of the oesophagus.
[MeSH-minor]
Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis.
Carcinoma
, Squamous Cell / chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Histopathology. 1998 Jan;32(1):7-14
[
9522210.001
]
[Cites]
J Cell Physiol. 1998 Sep;176(3):482-94
[
9699501.001
]
[Cites]
Cancer. 1998 Sep 1;83(5):858-66
[
9731887.001
]
[Cites]
Chest. 1999 Dec;116(6 Suppl):463S-465S
[
10619509.001
]
[Cites]
Mol Pathol. 1999 Aug;52(4):189-96
[
10694938.001
]
[Cites]
Mol Pathol. 1999 Aug;52(4):208-13
[
10694941.001
]
[Cites]
Int J Oncol. 2000 Apr;16(4):677-82
[
10717234.001
]
[Cites]
Int J Oncol. 2000 Apr;16(4):725-9
[
10717240.001
]
[Cites]
Genes Dev. 2000 Aug 1;14(15):1837-51
[
10921899.001
]
[Cites]
Br J Surg. 2000 Aug;87(8):992-1005
[
10931041.001
]
[Cites]
J Cell Biol. 2000 Aug 7;150(3):567-80
[
10931868.001
]
[Cites]
Int J Oncol. 2000 Oct;17(4):701-5
[
10995880.001
]
[Cites]
Breast Cancer. 2000 Jan;7(1):19-26
[
11029766.001
]
[Cites]
Cell Biol Int. 2001;25(1):61-9
[
11237409.001
]
[Cites]
Clin Chem. 2001 Apr;47(4):624-30
[
11274010.001
]
[Cites]
Oncol Rep. 2001 Sep-Oct;8(5):981-5
[
11496302.001
]
[Cites]
Clin Cancer Res. 2001 Nov;7(11):3519-25
[
11705871.001
]
[Cites]
J Clin Invest. 2002 Apr;109(8):999-1006
[
11956235.001
]
[Cites]
J Cell Biol. 1991 Sep;114(5):1059-68
[
1874786.001
]
[Cites]
Annu Rev Biochem. 1991;60:155-90
[
1883195.001
]
[Cites]
J Clin Lab Anal. 1991;5(5):344-66
[
1941355.001
]
[Cites]
J Cell Biol. 1991 Dec;115(6):1751-61
[
1757472.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292-6
[
1372439.001
]
[Cites]
Cell. 1992 Apr 3;69(1):11-25
[
1555235.001
]
[Cites]
Cell. 1992 Apr 17;69(2):225-36
[
1568244.001
]
[Cites]
J Pathol. 1992 May;167(1):77-82
[
1625062.001
]
[Cites]
J Pathol. 1992 Jun;167(2):187-91
[
1378891.001
]
[Cites]
Cell. 1992 Jul 24;70(2):293-301
[
1638632.001
]
[Cites]
Lancet. 1992 Oct 31;340(8827):1053-8
[
1357452.001
]
[Cites]
Br J Cancer. 1992 Oct;66(4):629-34
[
1384639.001
]
[Cites]
J Cell Biol. 1993 Feb;120(3):577-85
[
8381117.001
]
[Cites]
Lancet. 1993 Mar 20;341(8847):725-6
[
8095628.001
]
[Cites]
Am J Pathol. 1993 Apr;142(4):981-6
[
7682766.001
]
[Cites]
Am J Pathol. 1993 Apr;142(4):987-93
[
7682767.001
]
[Cites]
J Surg Oncol. 1993 Jun;53(2):78-83
[
8501910.001
]
[Cites]
Br J Cancer. 1993 Jul;68(1):122-4
[
7686390.001
]
[Cites]
J Cell Biol. 1993 Jul;122(2):431-42
[
8320265.001
]
[Cites]
Br J Cancer. 1993 Aug;68(2):428-32
[
8347502.001
]
[Cites]
Cancer Res. 1993 Sep 15;53(18):4197-203
[
7689929.001
]
[Cites]
J Biol Chem. 1993 Oct 25;268(30):22883-94
[
8226797.001
]
[Cites]
Nature. 1993 Dec 16;366(6456):630-1
[
7505052.001
]
[Cites]
Nature. 1993 Dec 16;366(6456):695-8
[
7505053.001
]
[Cites]
Cancer Res. 1994 Jan 1;54(1):291-6
[
8261454.001
]
[Cites]
Cell. 1994 Jan 28;76(2):301-14
[
7507411.001
]
[Cites]
J Cell Biol. 1994 Feb;124(4):589-600
[
8106556.001
]
[Cites]
Cancer. 1994 Mar 1;73(5):1324-31
[
7906606.001
]
[Cites]
Cancer Res. 1994 Jun 1;54(11):3007-10
[
8187090.001
]
[Cites]
J Cell Biol. 1994 Jun;125(6):1327-40
[
8207061.001
]
[Cites]
J Cell Biol. 1994 Jul;126(2):391-401
[
7518464.001
]
[Cites]
Semin Oncol. 1994 Aug;21(4):425-30
[
8042040.001
]
[Cites]
J Cell Biol. 1994 Aug;126(4):1099-109
[
7519619.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8263-7
[
8058792.001
]
[Cites]
Blood. 1994 Oct 1;84(7):2068-101
[
7522621.001
]
[Cites]
J Biol Chem. 1994 Oct 28;269(43):26602-5
[
7929388.001
]
[Cites]
J Cell Physiol. 1997 Oct;173(1):54-63
[
9326449.001
]
[Cites]
J Pathol. 1997 Jul;182(3):331-8
[
9349237.001
]
[Cites]
Blood. 1997 Nov 15;90(10):4039-45
[
9354673.001
]
[Cites]
Int J Cancer. 1997 Dec 19;74(6):582-7
[
9421352.001
]
[Cites]
Am J Pathol. 1998 Jan;152(1):135-44
[
9422531.001
]
[Cites]
J Cell Biol. 1997 Jun 16;137(6):1421-31
[
9182672.001
]
[Cites]
Cancer. 1998 Sep 15;83(6):1074-80
[
9740070.001
]
[Cites]
Clin Cancer Res. 1996 Jul;2(7):1097-102
[
9816273.001
]
[Cites]
Cell. 1996 Oct 18;87(2):175-85
[
8861902.001
]
[Cites]
Science. 1996 Nov 15;274(5290):1123-33
[
8895455.001
]
[Cites]
Dev Biol. 1996 Dec 15;180(2):402-12
[
8954713.001
]
[Cites]
Br J Surg. 1996 Nov;83(11):1608-14
[
9014688.001
]
[Cites]
Clin Cancer Res. 1998 Feb;4(2):407-10
[
9516929.001
]
[Cites]
J Clin Invest. 1997 Jul 1;100(1):1-5
[
9202049.001
]
[Cites]
EMBO J. 1997 Jul 1;16(13):3797-804
[
9233789.001
]
[Cites]
J Pathol. 1998 Sep;186(1):1-2
[
9875132.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44
[
9874785.001
]
[Cites]
J Cell Biol. 1999 Mar 22;144(6):1311-22
[
10087272.001
]
[Cites]
Semin Cancer Biol. 1999 Apr;9(2):67-81
[
10202129.001
]
[Cites]
Am J Med. 1999 Apr;106(4):467-76
[
10225251.001
]
[Cites]
Am J Pathol. 1999 Apr;154(4):965-73
[
10233832.001
]
[Cites]
Hepatogastroenterology. 1999 Mar-Apr;46(26):938-43
[
10370643.001
]
[Cites]
Cell Growth Differ. 1999 Jun;10(6):369-76
[
10392898.001
]
[Cites]
J Biol Chem. 1999 Jul 23;274(30):21409-15
[
10409703.001
]
[Cites]
Curr Opin Cell Biol. 1999 Oct;11(5):591-6
[
10508646.001
]
[Cites]
J Exp Med. 1965 Mar 1;121:439-62
[
14270243.001
]
[Cites]
Anticancer Res. 2002 May-Jun;22(3):1849-57
[
12168881.001
]
[Cites]
J Cell Biol. 2002 Sep 2;158(5):953-65
[
12213839.001
]
[Cites]
World J Gastroenterol. 2003 Feb;9(2):225-32
[
12532436.001
]
[Cites]
Surgery. 2003 Feb;133(2):162-9
[
12605177.001
]
[Cites]
Anticancer Res. 2003 Jan-Feb;23(1A):161-5
[
12680208.001
]
[Cites]
J Neurosurg. 2003 May;98(5):1084-93
[
12744370.001
]
[Cites]
Anticancer Res. 2003 Nov-Dec;23(6a):4435-42
[
14666731.001
]
[Cites]
Cancer Res. 1986 Jan;46(1):1-7
[
2998604.001
]
[Cites]
J Cell Biol. 1987 May;104(5):1361-74
[
3553211.001
]
[Cites]
J Exp Med. 1987 Oct 1;166(4):1125-31
[
3655655.001
]
[Cites]
J Pathol. 1988 Jul;155(3):207-12
[
3411381.001
]
[Cites]
Development. 1988 Apr;102(4):639-55
[
3048970.001
]
[Cites]
Biochim Biophys Acta. 1988 Nov 15;948(2):175-224
[
3052592.001
]
[Cites]
Cell. 1989 Apr 21;57(2):327-34
[
2702691.001
]
[Cites]
Science. 1989 Dec 8;246(4935):1303-6
[
2588007.001
]
[Cites]
Science. 1990 Jan 5;247(4938):49-56
[
2294591.001
]
[Cites]
Cancer Res. 1990 Feb 15;50(4):1271-8
[
1967552.001
]
[Cites]
J Cell Biol. 1990 Feb;110(2):349-57
[
2153683.001
]
[Cites]
Cell. 1990 Feb 23;60(4):577-84
[
1689216.001
]
[Cites]
Cancer Metastasis Rev. 1989 Dec;8(3):263-80
[
2697474.001
]
[Cites]
Science. 1990 Mar 9;247(4947):1219-22
[
1690453.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4246-50
[
2349235.001
]
[Cites]
Cell. 1990 Jun 29;61(7):1303-13
[
1694723.001
]
[Cites]
Nature. 1990 Aug 2;346(6283):425-34
[
1974032.001
]
[Cites]
FASEB J. 1990 Aug;4(11):2868-80
[
2199285.001
]
[Cites]
Lab Invest. 1990 Dec;63(6):780-91
[
1979361.001
]
[Cites]
Cell. 1991 May 31;65(5):849-57
[
1904011.001
]
[Cites]
Cell. 1991 Jul 12;66(1):107-19
[
2070412.001
]
[Cites]
Cancer Res. 1994 Dec 1;54(23):6282-7
[
7954478.001
]
[Cites]
Gut. 1994 Oct;35(10):1343-7
[
7959182.001
]
[Cites]
J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9
[
7806582.001
]
[Cites]
Curr Opin Cell Biol. 1994 Oct;6(5):663-73
[
7530461.001
]
[Cites]
Cell. 1995 Feb 10;80(3):413-22
[
7532110.001
]
[Cites]
Nature. 1995 Mar 23;374(6520):327-37
[
7885471.001
]
[Cites]
J Biol Chem. 1995 Mar 10;270(10):5549-55
[
7890674.001
]
[Cites]
J Cell Biol. 1995 Jul;130(1):67-77
[
7790378.001
]
[Cites]
FASEB J. 1995 Jul;9(10):866-73
[
7542213.001
]
[Cites]
J Cell Biol. 1995 Jul;130(2):451-60
[
7542249.001
]
[Cites]
Mol Biol Cell. 1995 Apr;6(4):419-31
[
7542940.001
]
[Cites]
J Clin Pathol. 1995 Jun;48(6):539-44
[
7665697.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8813-7
[
7568023.001
]
[Cites]
J Pathol. 1995 Sep;177(1):11-20
[
7472774.001
]
[Cites]
Am J Pathol. 1995 Dec;147(6):1823-39
[
7495306.001
]
[Cites]
Curr Opin Cell Biol. 1995 Oct;7(5):634-40
[
8573337.001
]
[Cites]
Science. 1996 Apr 5;272(5258):60-6
[
8600538.001
]
[Cites]
Cancer Lett. 1996 Apr 19;102(1-2):183-91
[
8603368.001
]
[Cites]
Br J Surg. 1996 May;83(5):588-601
[
8689199.001
]
[Cites]
Oncology. 1997 Mar-Apr;54(2):158-65
[
9075789.001
]
[Cites]
Trends Genet. 1997 Apr;13(4):157-62
[
9097727.001
]
[Cites]
Proc Soc Exp Biol Med. 1999 Nov;222(2):124-38
[
10564536.001
]
[Cites]
Gut. 2000 Jan;46(1):14-9
[
10601048.001
]
(PMID = 15790695.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD44; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Integrins; 0 / Selectins
[Number-of-references]
132
[Other-IDs]
NLM/ PMC1770622
26.
Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, Glynne-Jones R:
Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?
Int J Radiat Oncol Biol Phys
; 2010 Nov 1;78(3):715-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Magnetic resonance imaging assessment of squamous cell
carcinoma
of the
anal
canal
before and after chemoradiation: can MRI predict for eventual clinical outcome?
PURPOSE: To describe the MRI appearances of squamous cell
carcinoma
of the
anal
canal
before and after chemoradiation and to assess whether MRI features predict for clinical outcome.
METHODS AND MATERIALS: Thirty-five patients (15 male, 20 female; mean age 60.8 years) with histologically proven squamous cell
cancer of
the
anal
canal
underwent MRI before and 6-8 weeks after definitive chemoradiation.
Images were reviewed retrospectively by two radiologists in consensus blinded to clinical outcome: tumor size, signal intensity, extent, and TNM
stage
were recorded.
[MeSH-major]
Anus
Neoplasms / pathology.
Carcinoma
, Squamous Cell / pathology. Magnetic Resonance Imaging
[MeSH-minor]
Anal
Canal
/ pathology. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Tumor Burden
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 20171812.001).
[ISSN]
1879-355X
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
27.
Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H:
Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
Langenbecks Arch Surg
; 2010 Nov;395(8):1031-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Neoadjuvant chemoradiotherapy for rectal
carcinoma
: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal
Cancer
Surgery multicenter observational trial.
INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal
cancer
patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal
cancer
patients using a representative data set from the Quality Assurance in Rectal
Cancer
Surgery multicenter observational trial.
METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal
Cancer
Surgery prospective multicenter observational trial.
Data of all patients undergoing curatively intended sphincter-preserving resection for UICC
stage I
through III rectal
carcinoma
between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
Significant differences were present between groups regarding age, sex, distance of the tumor from the
anal
verge, pT-
stage
, UICC
stage
, hepatic risk factors, and use of protective enterostomy by univariate analysis.
CONCLUSION: Neoadjuvant chemoradiotherapy for rectal
carcinoma
does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.
[MeSH-major]
Anal
Canal
/ surgery. Anastomotic Leak / etiology. Neoadjuvant Therapy. Postoperative Complications / etiology. Quality Assurance, Health Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectum / surgery. Urinary Bladder Diseases / etiology
Genetic Alliance.
consumer health - Rectal Cancer
.
Genetic Alliance.
consumer health - Bladder cancer
.
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Bladder Diseases
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Langenbecks Arch Surg. 2007 Mar;392(2):179-88
[
17279430.001
]
[Cites]
Dis Colon Rectum. 2008 Aug;51(8):1195-201
[
18523823.001
]
[Cites]
Zentralbl Chir. 2006 Aug;131(4):275-84
[
17004186.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):129-36
[
19304407.001
]
[Cites]
Int J Colorectal Dis. 2008 Mar;23(3):257-64
[
18071720.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Cancer. 1990 Jul 1;66(1):49-55
[
2191763.001
]
[Cites]
Z Gastroenterol. 2008 Aug;46(8):799-840
[
18759205.001
]
[Cites]
Chirurg. 2009 Apr;80(4):303-10
[
19350307.001
]
[Cites]
Ann Surg. 2005 Oct;242(4):502-10; discussion 510-1
[
16192810.001
]
[Cites]
Int MS J. 2009 Sep;16(3):90-7
[
19878631.001
]
[Cites]
Dis Colon Rectum. 2005 Oct;48(10):1868-74
[
16175323.001
]
[Cites]
Br J Surg. 2006 Dec;93(12):1519-25
[
17054311.001
]
[Cites]
JAMA. 2000 Aug 23-30;284(8):1008-15
[
10944647.001
]
[Cites]
Br J Surg. 2001 Nov;88(11):1501-5
[
11683749.001
]
[Cites]
Chirurg. 2009 Apr;80(4):266-73
[
19271158.001
]
[Cites]
J Clin Oncol. 2002 Feb 1;20(3):817-25
[
11821466.001
]
[Cites]
Langenbecks Arch Surg. 2007 Sep;392(5):525-33
[
17394012.001
]
[Cites]
Chirurg. 2003 May;74(5):444-50; discussion 450-1
[
12748793.001
]
[Cites]
Surg Oncol. 2007 Dec;16 Suppl 1:S83-9
[
18042378.001
]
[Cites]
Int J Colorectal Dis. 2003 Nov;18(6):495-9
[
14517686.001
]
[Cites]
N Engl J Med. 2004 Oct 21;351(17):1731-40
[
15496622.001
]
[Cites]
Ann Surg Oncol. 2007 May;14(5):1744-51
[
17334851.001
]
[Cites]
J Gastrointest Surg. 2009 Mar;13(3):521-5
[
19011946.001
]
[Cites]
Eur J Surg Oncol. 2006 Dec;32(10):1201-8
[
16872799.001
]
[Cites]
Acta Oncol. 2003;42(5-6):476-92
[
14596508.001
]
[Cites]
Dis Colon Rectum. 2002 Jul;45(7):934-9
[
12130883.001
]
[Cites]
Colorectal Dis. 2007 Nov;9(9):801-7
[
17931170.001
]
[Cites]
Dis Colon Rectum. 2003 May;46(5):621-8
[
12792438.001
]
[Cites]
Am Surg. 2004 Dec;70(12):1045-9
[
15663042.001
]
[Cites]
Cancer. 1996 Sep 1;78(5):968-76
[
8780533.001
]
[Cites]
J Clin Oncol. 2005 Sep 1;23(25):6199-206
[
16135487.001
]
[Cites]
Ann Surg Oncol. 1996 Sep;3(5):423-30
[
8876883.001
]
[Cites]
J Clin Oncol. 2005 Sep 1;23(25):6126-31
[
16135478.001
]
[Cites]
Colorectal Dis. 2004 Nov;6(6):462-9
[
15521937.001
]
[Cites]
Zentralbl Chir. 2009 Jun;134(3):242-8
[
19536719.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20
[
12654443.001
]
[Cites]
Eur J Surg. 1996 May;162(5):397-402
[
8781922.001
]
[Cites]
Lancet. 2001 Oct 20;358(9290):1291-304
[
11684209.001
]
(PMID = 20711786.001).
[ISSN]
1435-2451
[Journal-full-title]
Langenbeck's archives of surgery
[ISO-abbreviation]
Langenbecks Arch Surg
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Multicenter Study
[Publication-country]
Germany
28.
Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ:
Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.
World J Gastroenterol
; 2008 Apr 28;14(16):2474-86
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Subsequently, nonalcoholic fatty liver disease (NAFLD) has been used as a general name for conditions ranging from simple steatosis through steatohepatitis to end-
stage
liver disease (cirrhosis).
Longitudinal cohort studies have demonstrated that those patients with cirrhosis have a similar risk to develop hepatocellular
carcinoma
as those with other causes of cirrhosis.
Genetic Alliance.
consumer health - Liver Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Gastroenterol Hepatol. 2006 May;4(5):639-44
[
16630771.001
]
[Cites]
Diabet Med. 2006 May;23(5):469-80
[
16681555.001
]
[Cites]
Diabetes. 2006 Jun;55(6):1537-45
[
16731815.001
]
[Cites]
Dig Liver Dis. 2006 Jul;38(7):485-9
[
16716779.001
]
[Cites]
N Engl J Med. 2006 Jun 15;354(24):2552-63
[
16775236.001
]
[Cites]
Minerva Cardioangiol. 2006 Apr;54(2):229-39
[
16778754.001
]
[Cites]
Radiology. 2006 Jul;240(1):116-29
[
16684918.001
]
[Cites]
J Gastroenterol. 2006 May;41(5):462-9
[
16799888.001
]
[Cites]
J Clin Invest. 2006 Jul;116(7):1767-75
[
16823474.001
]
[Cites]
Gastroenterology. 2006 Sep;131(3):934-45
[
16952562.001
]
[Cites]
Eur Radiol. 2006 Oct;16(10):2292-308
[
16477402.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54
[
16608888.001
]
[Cites]
Hepatology. 2006 Oct;44(4):802-5
[
17006914.001
]
[Cites]
Hepatology. 2006 Oct;44(4):865-73
[
17006923.001
]
[Cites]
Ann Intern Med. 2006 Mar 7;144(5):379; author reply 380
[
16520485.001
]
[Cites]
Dig Dis Sci. 2006 Feb;51(2):346-51
[
16534679.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2006 Apr;18(4):411-2
[
16538113.001
]
[Cites]
J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S11-6
[
16540761.001
]
[Cites]
Gastroenterology. 2002 Nov;123(5):1702-4
[
12404244.001
]
[Cites]
Gastroenterology. 2002 Nov;123(5):1705-25
[
12404245.001
]
[Cites]
Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi
[
17544979.001
]
[Cites]
N Engl J Med. 2007 Jun 14;356(24):2457-71
[
17517853.001
]
[Cites]
Med Mol Morphol. 2007 Jun;40(2):55-67
[
17572841.001
]
[Cites]
Hepatology. 2007 Jul;46(1):122-9
[
17526015.001
]
[Cites]
N Engl J Med. 2007 Jul 5;357(1):28-38
[
17551159.001
]
[Cites]
Horm Res. 2007;68(2):72-82
[
17344645.001
]
[Cites]
J Biol Chem. 2002 Sep 13;277(37):34182-90
[
12097330.001
]
[Cites]
Dig Dis Sci. 2007 Oct;52(10):2512-9
[
17404856.001
]
[Cites]
Annu Rev Nutr. 2007;27:179-92
[
17428181.001
]
[Cites]
Nature. 1999 Dec 9;402(6762):656-60
[
10604470.001
]
[Cites]
Am J Gastroenterol. 2000 Jan;95(1):272-6
[
10638596.001
]
[Cites]
Cleve Clin J Med. 2000 Feb;67(2):96-7, 101-4
[
10680276.001
]
[Cites]
J Pediatr. 2000 Jun;136(6):734-8
[
10839868.001
]
[Cites]
Br J Nutr. 2000 Mar;83 Suppl 1:S5-8
[
10889785.001
]
[Cites]
Mol Cell. 2000 Jul;6(1):77-86
[
10949029.001
]
[Cites]
Nat Med. 2000 Sep;6(9):998-1003
[
10973319.001
]
[Cites]
Eur J Pharmacol. 2000 Oct 6;406(1):R5-7
[
11011050.001
]
[Cites]
Genes Dev. 2000 Nov 15;14(22):2831-8
[
11090131.001
]
[Cites]
Trends Endocrinol Metab. 2003 Nov;14(9):398-403
[
14580758.001
]
[Cites]
Am J Med. 2003 Nov;115(7):554-9
[
14599635.001
]
[Cites]
Am J Gastroenterol. 2003 Nov;98(11):2485-90
[
14638353.001
]
[Cites]
Endocr Pract. 2003 Sep-Oct;9 Suppl 2:93-6
[
14698985.001
]
[Cites]
Hepatology. 2004 Jan;39(1):188-96
[
14752837.001
]
[Cites]
Aliment Pharmacol Ther. 2004 Mar 1;19(5):537-44
[
14987322.001
]
[Cites]
Hepatology. 2004 Mar;39(3):754-63
[
14999694.001
]
[Cites]
Hepatology. 2004 Mar;39(3):770-8
[
14999696.001
]
[Cites]
Hepatology. 2004 Apr;39(4):1172; author reply 1173
[
15057921.001
]
[Cites]
Curr Opin Pediatr. 2005 Oct;17(5):636-41
[
16160540.001
]
[Cites]
Liver Int. 2005 Oct;25(5):921-6
[
16162147.001
]
[Cites]
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:3-10
[
16225463.001
]
[Cites]
Turk J Gastroenterol. 2005 Sep;16(3):124-8
[
16245220.001
]
[Cites]
Hepatology. 2005 Nov;42(5):987-1000
[
16250043.001
]
[Cites]
Gastroenterology. 2005 Nov;129(5):1805
[
16285987.001
]
[Cites]
Ann Intern Med. 2005 Nov 15;143(10):722-8
[
16287793.001
]
[Cites]
Radiology. 2005 Dec;237(3):1048-55
[
16237138.001
]
[Cites]
Am J Med Sci. 2005 Dec;330(6):280-9
[
16355012.001
]
[Cites]
Hepatology. 2006 Jan;43(1):64-71
[
16374856.001
]
[Cites]
Gastroenterology. 2006 Jan;130(1):207-10
[
16401483.001
]
[Cites]
Nihon Koshu Eisei Zasshi. 2005 Nov;52(11):934-42
[
16408478.001
]
[Cites]
Mitochondrion. 2006 Feb;6(1):1-28
[
16406828.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96
[
16493415.001
]
[Cites]
Ann Intern Med. 2006 Mar 7;144(5):379-80; author reply 380
[
16520484.001
]
[Cites]
Curr Opin Gastroenterol. 2007 Mar;23(2):193-8
[
17268250.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Feb;92(2):532-41
[
17118991.001
]
[Cites]
Am J Med. 2007 Feb;120(2 Suppl 1):S9-17; discussion S29-32
[
17296344.001
]
[Cites]
Nutr Metab Cardiovasc Dis. 2007 Feb;17(2):125-39
[
17270403.001
]
[Cites]
Transl Res. 2007 Mar;149(3):114-25
[
17320797.001
]
[Cites]
Clin Chem. 2007 Apr;53(4):686-92
[
17272484.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Apr;92(4):1305-10
[
17264176.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Apr;92(4):1232-4
[
17409342.001
]
[Cites]
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1108-14
[
17303778.001
]
[Cites]
Diab Vasc Dis Res. 2007 Mar;4(1):32-8
[
17469041.001
]
[Cites]
Hepatology. 2007 May;45(5):1108-17
[
17464987.001
]
[Cites]
Gastroenterology. 2007 May;132(6):2087-102
[
17498505.001
]
[Cites]
Gastroenterology. 2007 May;132(6):2169-80
[
17498510.001
]
[Cites]
Nature. 2001 Jan 18;409(6818):307-12
[
11201732.001
]
[Cites]
Nature. 2001 Feb 8;409(6821):729-33
[
11217863.001
]
[Cites]
Endocr Pract. 2001 Jan-Feb;7(1):44-51
[
11250769.001
]
[Cites]
Liver Transpl. 2001 May;7(5):409-14
[
11349260.001
]
[Cites]
Am J Gastroenterol. 2001 May;96(5):1631-4
[
11374713.001
]
[Cites]
Anal Biochem. 2001 Jul 1;294(1):73-82
[
11412008.001
]
[Cites]
Nat Med. 2001 Jul;7(7):827-32
[
11433348.001
]
[Cites]
Eur J Ultrasound. 2001 Dec;14(2-3):121-8
[
11704429.001
]
[Cites]
Obes Res. 2001 Nov;9 Suppl 4:228S-233S
[
11707546.001
]
[Cites]
Hepatology. 2001 Dec;34(6):1158-63
[
11732005.001
]
[Cites]
N Engl J Med. 2002 Feb 21;346(8):570-8
[
11856796.001
]
[Cites]
Gut. 2001 Feb;48(2):206-11
[
11156641.001
]
[Cites]
J Biol Chem. 2004 May 7;279(19):20314-26
[
14985368.001
]
[Cites]
Curr Opin Investig Drugs. 2004 Apr;5(4):389-94
[
15134279.001
]
[Cites]
J Gastroenterol. 2004;39(4):391-6
[
15168253.001
]
[Cites]
Eur J Heart Fail. 2004 Jun;6(4):501-8
[
15182777.001
]
[Cites]
Clin Liver Dis. 2004 Aug;8(3):575-94, ix
[
15331065.001
]
[Cites]
J Clin Gastroenterol. 2005 Aug;39(7):619-25
[
16000931.001
]
[Cites]
Gastroenterology. 2005 Jul;129(1):113-21
[
16012941.001
]
[Cites]
Gastroenterology. 2005 Jul;129(1):375-8
[
16012969.001
]
[Cites]
Nature. 2005 Jul 21;436(7049):356-62
[
16034410.001
]
[Cites]
Diabetes. 2005 Sep;54(9):2668-73
[
16123356.001
]
[Cites]
Hepatology. 2005 Sep;42(3):650-6
[
16037946.001
]
[Cites]
J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S34-8
[
16540765.001
]
[Cites]
Magn Reson Med. 2006 Apr;55(4):913-7
[
16506186.001
]
[Cites]
Clin Endocrinol (Oxf). 2006 Apr;64(4):355-65
[
16584505.001
]
[Cites]
Obesity (Silver Spring). 2006 Feb;14 Suppl 1:16S-19S
[
16642958.001
]
[Cites]
Mayo Clin Proc. 2006 Dec;81(12):1615-20
[
17165640.001
]
[Cites]
Nature. 2006 Dec 14;444(7121):840-6
[
17167471.001
]
[Cites]
Nature. 2006 Dec 14;444(7121):847-53
[
17167472.001
]
[Cites]
Eur J Radiol. 2007 Jan;61(1):33-43
[
17118603.001
]
[Cites]
Diabet Med. 2007 Jan;24(1):1-6
[
17227317.001
]
[Cites]
Cochrane Database Syst Rev. 2007;(1):CD005160
[
17253541.001
]
[Cites]
Cochrane Database Syst Rev. 2007;(1):CD005165
[
17253543.001
]
[Cites]
Cochrane Database Syst Rev. 2007;(1):CD005166
[
17253544.001
]
[Cites]
J Clin Invest. 2002 May;109(9):1125-31
[
11994399.001
]
[Cites]
Ann N Y Acad Sci. 2002 Jun;967:379-88
[
12079865.001
]
[Cites]
Pharmacol Ther. 2002 Aug;95(2):103-17
[
12182958.001
]
[Cites]
Am J Gastroenterol. 2002 Aug;97(8):2117-9
[
12190187.001
]
[Cites]
Gastroenterology. 2002 Sep;123(3):745-50
[
12198701.001
]
[Cites]
J R Soc Med. 2002;95 Suppl 42:39-45
[
12216326.001
]
[Cites]
Clin Liver Dis. 2004 Aug;8(3):619-38, x
[
15331067.001
]
[Cites]
Indian J Gastroenterol. 2004 Jul-Aug;23(4):131-4
[
15333967.001
]
[Cites]
Aliment Pharmacol Ther. 2004 Sep 15;20(6):623-8
[
15352910.001
]
[Cites]
Am J Gastroenterol. 2004 Oct;99(10):1946-52
[
15447754.001
]
[Cites]
Science. 2004 Oct 15;306(5695):457-61
[
15486293.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1095-105
[
15489566.001
]
[Cites]
Ann Hepatol. 2004 Jul-Sep;3(3):108-12
[
15505596.001
]
[Cites]
Mayo Clin Proc. 1980 Jul;55(7):434-8
[
7382552.001
]
[Cites]
Mol Pharmacol. 1988 Nov;34(5):605-13
[
2848184.001
]
[Cites]
Nature. 1990 Aug 9;346(6284):561-4
[
2165569.001
]
[Cites]
Nature. 1993 Sep 2;365(6441):61-5
[
7689702.001
]
[Cites]
Nature. 1994 Dec 1;372(6505):425-32
[
7984236.001
]
[Cites]
J Clin Invest. 1995 May;95(5):2409-15
[
7738205.001
]
[Cites]
Eur J Biochem. 1995 Aug 15;232(1):54-61
[
7556170.001
]
[Cites]
Biochem Biophys Res Commun. 1996 Apr 16;221(2):286-9
[
8619847.001
]
[Cites]
Hepatology. 1998 Jan;27(1):128-33
[
9425928.001
]
[Cites]
Gastroenterology. 1998 Apr;114(4):842-5
[
9547102.001
]
[Cites]
FASEB J. 1998 Aug;12(11):1035-44
[
9707176.001
]
[Cites]
Am J Physiol. 1999 May;276(5 Pt 1):E977-89
[
10329993.001
]
[Cites]
J Hepatol. 1999 Aug;31(2):384
[
10453959.001
]
[Cites]
Dtsch Med Wochenschr. 1962 May 18;87:1049-55
[
13920482.001
]
[Cites]
Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:180-210
[
13920484.001
]
[Cites]
Hepatology. 2004 Dec;40(6):1387-95
[
15565570.001
]
[Cites]
Am J Gastroenterol. 2004 Dec;99(12):2365-8
[
15571584.001
]
[Cites]
Mutat Res. 2005 Jan 6;569(1-2):101-10
[
15603755.001
]
[Cites]
Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15
[
15625656.001
]
[Cites]
Biochimie. 2005 Jan;87(1):57-64
[
15733738.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Mar;90(3):1578-82
[
15598693.001
]
[Cites]
Front Biosci. 2005;10:1520-33
[
15769642.001
]
[Cites]
Lancet. 2005 Apr 16-22;365(9468):1389-97
[
15836887.001
]
[Cites]
Am J Gastroenterol. 2005 May;100(5):1072-81
[
15842581.001
]
[Cites]
Am J Gastroenterol. 2005 May;100(5):1082-90
[
15842582.001
]
[Cites]
J Clin Invest. 2005 May;115(5):1298-305
[
15864349.001
]
[Cites]
J Clin Invest. 2005 May;115(5):1343-51
[
15864352.001
]
[Cites]
Int J Clin Pract. 2006 Dec;60(12):1697-706
[
17109677.001
]
[Cites]
BMC Gastroenterol. 2006;6:34
[
17096854.001
]
[Cites]
N Engl J Med. 2006 Nov 30;355(22):2297-307
[
17135584.001
]
[Cites]
Metabolism. 2006 Dec;55(12):1604-9
[
17142131.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Dec;91(12):4753-61
[
16968800.001
]
[Cites]
Best Pract Res Clin Endocrinol Metab. 2006 Dec;20(4):665-79
[
17161338.001
]
[Cites]
J Biol Chem. 2002 Nov 29;277(48):45904-10
[
12270935.001
]
[Cites]
Nature. 2002 Nov 21;420(6913):333-6
[
12447443.001
]
[Cites]
Hepatology. 2003 Mar;37(3):544-50
[
12601351.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2003 May;15(5):539-43
[
12702913.001
]
[Cites]
Am J Gastroenterol. 2003 Apr;98(4):926-30
[
12738478.001
]
[Cites]
Braz J Med Biol Res. 2003 Jun;36(6):723-9
[
12792701.001
]
[Cites]
J Clin Invest. 2003 Jul;112(1):91-100
[
12840063.001
]
[Cites]
Rom J Gastroenterol. 2003 Sep;12(3):189-92
[
14502318.001
]
[Cites]
Hepatology. 2003 Oct;38(4):1008-17
[
14512888.001
]
[Cites]
Hepatology. 2003 Nov;38(5):1167-77
[
14578855.001
]
(PMID = 18442193.001).
[ISSN]
2219-2840
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
China
[Chemical-registry-number]
0 / Fatty Acids, Nonesterified; 0 / Leptin; 0 / Lipids
[Number-of-references]
152
[Other-IDs]
NLM/ PMC2708357
29.
Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P:
Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
Crit Rev Oncol Hematol
; 2007 Mar;61(3):261-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal carcinoma
of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell
anal
cancer
.
There were 9
stage I
, 29
stage
II, 11
stage
IIIa and 13
stage
IIIb.
RESULTS:
Stage
II fared significantly better than
stage
III in terms of locoregional control (LRC) but not overall survival (OS).
[MeSH-major]
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / drug therapy.
Carcinoma
, Squamous Cell / radiotherapy
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17085056.001).
[ISSN]
1040-8428
[Journal-full-title]
Critical reviews in oncology/hematology
[ISO-abbreviation]
Crit. Rev. Oncol. Hematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
30.
Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M:
[Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Cancer Radiother
; 2006 Dec;10(8):572-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Epidermoid carcinomas of
anal
canal
treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
[Transliterated title]
Carcinomes épidermoïdes
du canal
anal
traités par association concomitante
de
radiothérapie et
de
chimiothérapie. Evaluation
des
résultats fonctionnels.
PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with
anal
cancer
.
The T-
stage
according to the 2001 UICC classification were: 2 T1, 26 T2, 25 T3, and 7 T4.
LC rate with a good
anal
function scoring (score 0 and 1) was 70%.
Among 43 pts who preserved their
anus
, 98% had a good
anal
function scoring.
Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the
anus
requiring colostomy and 1 pt with grade 3 rectal bleeding.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / drug therapy.
Carcinoma
, Squamous Cell / radiotherapy
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Anal
Canal
/ pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome
MedlinePlus Health Information.
consumer health - Anal Cancer
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17110148.001).
[ISSN]
1278-3218
[Journal-full-title]
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
[ISO-abbreviation]
Cancer Radiother
[Language]
fre
[Publication-type]
Comparative Study; English Abstract; Evaluation Studies; Journal Article
[Publication-country]
France
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
31.
Bretagnol F, Merrie A, George B, Warren BF, Mortensen NJ:
Local excision of rectal tumours by transanal endoscopic microsurgery.
Br J Surg
; 2007 May;94(5):627-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, its role in the curative treatment of invasive
carcinoma
is controversial.
The median tumour distance from the
anal
verge was 8 (range 1-16) cm.
Histological examination of carcinomas revealed pathological tumour (pT)
stage
1 in 31 patients, pT2 in 17 and pT3 in four.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Br J Surg. 2007 Sep;94(9):1179; author reply 1179
[
17701963.001
]
(PMID = 17335125.001).
[ISSN]
0007-1323
[Journal-full-title]
The British journal of surgery
[ISO-abbreviation]
Br J Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
32.
Kato T, Takagi H, Mori Y, Sakamoto K, Yamada T, Umeda Y, Fukumoto Y, Hirose H:
Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer.
Heart Vessels
; 2005 Jul;20(4):167-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal
cancer
.
A 68-year-old man with ischemic heart disease, abdominal aortic aneurysm, and rectal
cancer
was referred.
Barium enema revealed stenosis 4 cm in length 5 cm inward from the
anal
verge, and an endoscopic finding was ulcerated type tumor with a clear margin and circumferential stenosis.
Histological examination of a biopsy specimen revealed adenocarcinoma, and the clinical
stage
in the Japanese classification of colorectal
carcinoma
was II according to other examinations.
Simultaneous operations were scheduled because of the jeopardized collaterals of the coronary arteries, rapid expansion of the aneurysm, and subileus due to
the cancer
.
The patient is doing well 12 months after the operation, without myocardial ischemic symptoms or recurrence of the
cancer
.
Genetic Alliance.
consumer health - Heart Disease
.
Genetic Alliance.
consumer health - Rectal Cancer
.
Genetic Alliance.
consumer health - Abdominal Aortic Aneurysm
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Tex Heart Inst J. 2000;27(1):19-23
[
10830623.001
]
[Cites]
Arch Surg. 1967 Sep;95(3):402-12
[
6035464.001
]
[Cites]
J Vasc Surg. 1991 Feb;13(2):248-51; discussion 251-2
[
1990166.001
]
[Cites]
World J Surg. 1999 Mar;23(3):248-51
[
9933694.001
]
[Cites]
Surg Today. 1995;25(2):131-5
[
7772915.001
]
[Cites]
Br J Anaesth. 1984 Apr;56(4):333-8
[
6370281.001
]
[Cites]
Arch Surg. 1984 Jul;119(7):792-4
[
6732490.001
]
[Cites]
J Cardiovasc Surg (Torino). 1995 Feb;36(1):61-9
[
7721927.001
]
[Cites]
Ann Vasc Surg. 1987 Dec;1(5):616-20
[
3333012.001
]
[Cites]
Ann Thorac Surg. 1999 Oct;68(4):1537-9
[
10543563.001
]
[Cites]
Surgery. 1987 Feb;101(2):150-5
[
3810485.001
]
[Cites]
J Vasc Surg. 1989 May;9(5):630-5; discussion 635-6
[
2724451.001
]
[Cites]
Ann Surg. 1966 Oct;164(4):678-99
[
5924789.001
]
[Cites]
Am J Surg. 1998 Aug;176(2):144-6
[
9737620.001
]
(PMID = 16025367.001).
[ISSN]
0910-8327
[Journal-full-title]
Heart and vessels
[ISO-abbreviation]
Heart Vessels
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
33.
Abbas A, Yang G, Fakih M:
Management of anal cancer in 2010. Part 2: current treatment standards and future directions.
Oncology (Williston Park)
; 2010 Apr 30;24(5):417-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of
anal
cancer
in 2010. Part 2: current treatment standards and future directions.
The treatment of
anal
squamous cell
cancer
with definitive chemoradiation is the gold-standard therapy for localized
anal
cancer
, primarily because of its sphincter-saving and colostomy-sparing potential.
In the concluding part of this review, we consider the data on chemoradiation with 5-FU/mitomycin vs radiation alone, chemoradiation with 5-FU/mitomycin vs chemoradiation with 5-FU alone, neoadjuvant chemotherapy with cisplatin/5-FU followed by cisplatin/5-FU plus radiation vs mitomycin/5-FU plus radiation, the addition of induction or maintenance chemotherapy to chemoradiation, the effect of overall treatment time on tumor control, whether chemotherapy can be eliminated for early-
stage anal
cancer
, and the impact of human immunodeficiency virus infection on treatment.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / drug therapy.
Carcinoma
, Squamous Cell / radiotherapy
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Oncology (Williston Park). 2010 Apr 30;24(5):427-30
[
20480742.001
]
[CommentIn]
Oncology (Williston Park). 2010 Apr 30;24(5):424-7
[
20480741.001
]
(PMID = 20480740.001).
[ISSN]
0890-9091
[Journal-full-title]
Oncology (Williston Park, N.Y.)
[ISO-abbreviation]
Oncology (Williston Park, N.Y.)
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
[Number-of-references]
52
34.
Dwyer MK, Gebski VJ, Jayamohan J:
The bottom line: outcomes after conservation treatment in anal cancer.
Australas Radiol
; 2006 Feb;50(1):46-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The bottom line: outcomes after conservation treatment in
anal
cancer
.
At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell
carcinoma
of
anal
canal
or margin (including 15 with
Stage
IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil).
Most patients with
anal
cancer
can expect to retain a functional sphincter after chemoradiation/radiation.
[MeSH-major]
Anus
Neoplasms / therapy.
Carcinoma
, Squamous Cell / therapy
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16499727.001).
[ISSN]
0004-8461
[Journal-full-title]
Australasian radiology
[ISO-abbreviation]
Australas Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
35.
Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A:
Patterns of failure and outcome in patients with carcinoma of the anal margin.
Ann Surg Oncol
; 2008 Apr;15(4):1092-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Patterns of failure and outcome in patients with
carcinoma
of the
anal
margin.
BACKGROUND: To evaluate the outcome of patients with
carcinoma
of
anal
margin in terms of recurrence, survival, and radiation toxicity.
METHODS: A series of 45 consecutive patients, with
anal
margin
carcinoma
treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
The overall
anal
conservation rate was 80% for the whole series.
There was no significant association between local recurrence and patient age, histological grade, tumor size, T
stage
, overall treatment time, RT dose, or chemotherapy.
[MeSH-major]
Anus
Neoplasms / therapy.
Carcinoma
, Basal Cell / therapy.
Carcinoma
, Squamous Cell / therapy
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Anal
Canal
/ surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18231838.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
36.
Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, Aust G:
Expression of ADAM15 in lung carcinomas.
Virchows Arch
; 2005 Apr;446(4):421-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung
carcinoma
cell lines and tissues.
Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell
cancer
(SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex.
Overall analysis of all tumor specimens and each tumor type revealed no significant correlation between tumor
stage
or degree of differentiation and ADAM15 ectosolic or cytosolic domain expression in tumor cells.
In summary, lung
carcinoma
cell lines and tissues were frequently ADAM15 positive.
[MeSH-major]
Adenocarcinoma / metabolism.
Carcinoma
, Squamous Cell / metabolism. Integrin alphaVbeta3 / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Metalloendopeptidases / metabolism
MedlinePlus Health Information.
consumer health - Lung Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gynecol Oncol. 1996 Aug;62(2):260-7
[
8751559.001
]
[Cites]
Biochem Biophys Res Commun. 1997 Jun 18;235(2):437-42
[
9199213.001
]
[Cites]
Am J Pathol. 1999 Oct;155(4):1033-8
[
10514384.001
]
[Cites]
J Cell Sci. 1999 Feb;112 ( Pt 4):579-87
[
9914169.001
]
[Cites]
J Biol Chem. 2002 Sep 13;277(37):33683-9
[
12091380.001
]
[Cites]
Differentiation. 1988;37(2):158-71
[
2840315.001
]
[Cites]
Haematologica. 2002 Aug;87(8):836-45
[
12161360.001
]
[Cites]
Curr Opin Cell Biol. 2003 Oct;15(5):598-606
[
14519395.001
]
[Cites]
Pathol Res Pract. 1998;194(10):701-4
[
9820866.001
]
[Cites]
Cancer Res. 2004 Mar 15;64(6):2062-9
[
15026344.001
]
[Cites]
J Biol Chem. 1998 Oct 2;273(40):26236-47
[
9748307.001
]
[Cites]
J Biol Chem. 2000 Nov 10;275(45):34922-30
[
10944520.001
]
[Cites]
J Biol Chem. 1996 Mar 1;271(9):4593-6
[
8617717.001
]
[Cites]
Thromb Haemost. 2003 Apr;89(4):622-31
[
12669115.001
]
[Cites]
J Cell Biol. 1996 Sep;134(5):1323-32
[
8794871.001
]
[Cites]
Cell. 1996 May 31;85(5):683-93
[
8646777.001
]
[Cites]
Mol Cell Biol. 2003 Aug;23(16):5614-24
[
12897135.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47
[
2424168.001
]
[Cites]
Mol Immunol. 1987 Jul;24(7):699-705
[
3309626.001
]
[Cites]
Trends Cell Biol. 1994 Jul;4(7):256-61
[
14731666.001
]
[Cites]
Eur Respir J. 1998 Feb;11(2):400-7
[
9551745.001
]
[Cites]
Clin Exp Metastasis. 2002;19(8):717-25
[
12553378.001
]
[Cites]
J Biol Chem. 2002 May 17;277(20):17804-10
[
11882657.001
]
[Cites]
Neoplasia. 2002 May-Jun;4(3):191-4
[
11988838.001
]
[Cites]
Oncol Res. 1993;5(10-11):441-51
[
8054705.001
]
[Cites]
Pathobiology. 2004;71(4):185-92
[
15263807.001
]
[Cites]
Biochem Soc Trans. 1999 Feb;27(2):255-9
[
10093743.001
]
[Cites]
Anal Biochem. 1984 Feb;136(2):458-64
[
6721145.001
]
[Cites]
Am J Pathol. 2002 Mar;160(3):1129-41
[
11891209.001
]
[Cites]
Pathol Int. 1995 Jul;45(7):493-500
[
7551009.001
]
[Cites]
J Cell Biol. 2004 Mar 15;164(6):935-41
[
15024036.001
]
[Cites]
Arthritis Rheum. 1999 Sep;42(9):1946-50
[
10513811.001
]
[Cites]
Arthritis Rheum. 2001 Sep;44(9):2046-54
[
11592366.001
]
[Cites]
Hum Pathol. 1997 Sep;28(9):1018-25
[
9308725.001
]
[Cites]
J Comp Neurol. 2003 Oct 6;465(1):1-10
[
12926012.001
]
[Cites]
J Biol Chem. 1998 Mar 27;273(13):7345-50
[
9516430.001
]
[Cites]
Int J Cancer. 1976 Jan 15;17(1):62-70
[
175022.001
]
[Cites]
Am J Pathol. 2001 Nov;159(5):1613-7
[
11696421.001
]
[Cites]
Cancer Res. 2004 Feb 15;64(4):1209-14
[
14973118.001
]
[Cites]
Am J Pathol. 1998 Nov;153(5):1347-51
[
9811323.001
]
[Cites]
Cancer Res. 1997 Apr 15;57(8):1554-60
[
9108459.001
]
[Cites]
Jpn J Cancer Res. 1996 May;87(5):451-8
[
8641981.001
]
[Cites]
J Biol Chem. 2000 May 19;275(20):15490-7
[
10809781.001
]
[Cites]
Genes Dev. 2003 Jan 1;17(1):7-30
[
12514095.001
]
[Cites]
Exp Cell Res. 2001 Nov 15;271(1):152-60
[
11697891.001
]
[Cites]
J Cell Biol. 1995 Oct;131(2):275-8
[
7593158.001
]
[Cites]
J Exp Med. 1999 Jan 4;189(1):169-78
[
9874573.001
]
[Cites]
FASEB J. 1997 Feb;11(2):173-80
[
9039960.001
]
[Cites]
J Cancer Res Clin Oncol. 1980 Jan;96(1):27-33
[
7358770.001
]
(PMID = 15756594.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Integrin alphaVbeta3; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM15 protein, human; EC 3.4.24.- / Metalloendopeptidases
37.
Dhamanaskar KP, Thurston W, Wilson SR:
Transvaginal sonography as an adjunct to endorectal sonography in the staging of rectal cancer in women.
AJR Am J Roentgenol
; 2006 Jul;187(1):90-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transvaginal sonography as an adjunct to endorectal sonography in the staging of rectal
cancer
in women.
OBJECTIVE: The purpose of this study was to evaluate the contribution of transvaginal sonography (TVS) in the staging of rectal
cancer
in women.
Forty-nine of the women had rectal
carcinoma
; nine, tubulovillous adenoma; and two, gastrointestinal stromal tumor confirmed at surgical pathologic examination (n = 41) and biopsy before chemoradiation therapy (n = 19).
Endorectal sonography was suboptimal for tumors that were stenotic (n = 3), large (n = 2), high at the rectosigmoid junction (n = 4), or low at the
anal
canal
(n = 3).
In these 12 cases, TVS successfully depicted the lesion, and the images gave enough information for prediction of
stage
.
CONCLUSION: TVS is an excellent adjunct to endorectal sonography in the staging of rectal
cancer
in women.
[MeSH-minor]
Adenoma, Villous / pathology. Adenoma, Villous / ultrasonography. Aged.
Carcinoma
/ pathology.
Carcinoma
/ ultrasonography. Female. Humans. Middle Aged. Sensitivity and Specificity. Vagina
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16794161.001).
[ISSN]
1546-3141
[Journal-full-title]
AJR. American journal of roentgenology
[ISO-abbreviation]
AJR Am J Roentgenol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
38.
Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y:
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Int J Urol
; 2006 Sep;13(9):1254-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell
carcinoma
of the prostate.
Small-cell
carcinoma
of the prostate (SCCP) is a rare entity.
Case 1 involved a 53-year-old man diagnosed with SCCP after receiving hormone therapy for prostate
cancer
(
stage
D1).
Initially the primary site reduced according with a decline of neuro-specific enolase and with relief of the symptoms; however, bone disease occurred and he died
of cancer
13 months after diagnosis of SCCP.
Case 2 involved a 69-year-old man complaining of severe
anal
pain.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Carcinoma
, Small Cell / drug therapy. Prostatic Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
DOCETAXEL
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16984566.001).
[ISSN]
0919-8172
[Journal-full-title]
International journal of urology : official journal of the Japanese Urological Association
[ISO-abbreviation]
Int. J. Urol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
39.
Uto H, Kanmura S, Takami Y, Tsubouchi H:
Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers.
Proteome Sci
; 2010;8:70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Hepatocellular
carcinoma
(HCC) is the fifth most common
cancer
and advanced hepatic fibrosis is a major risk factor for HCC.
Early diagnosis of HCC and assessment of the
stage
of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic interventions and an improve prognosis.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Proteome Res. 2010 Apr 5;9(4):1923-30
[
20121168.001
]
[Cites]
J Cancer Res Clin Oncol. 2010 Aug;136(8):1151-9
[
20130913.001
]
[Cites]
Proteome Sci. 2010;8:5
[
20181094.001
]
[Cites]
Biochemistry (Mosc). 2009 Dec;74(13):1575-85
[
20210710.001
]
[Cites]
J Proteome Res. 2010 Jun 4;9(6):3218-24
[
20441224.001
]
[Cites]
Hepatology. 1994 Jan;19(1):61-6
[
7506227.001
]
[Cites]
Clin Chem. 2005 Feb;51(2):328-35
[
15590748.001
]
[Cites]
J Proteome Res. 2005 Mar-Apr;4(2):377-86
[
15822913.001
]
[Cites]
Anal Bioanal Chem. 2005 Jun;382(3):669-78
[
15900442.001
]
[Cites]
Hepatology. 2005 Sep;42(3):665-74
[
16116632.001
]
[Cites]
Clin Chem. 2005 Dec;51(12):2236-44
[
16239339.001
]
[Cites]
Proteomics. 2006 Feb;6(3):1049-57
[
16400691.001
]
[Cites]
Proteomics. 2006 May;6(9):2895-902
[
16586431.001
]
[Cites]
Gastroenterology. 2006 Jun;130(7):2189-97
[
16762639.001
]
[Cites]
J Proteome Res. 2006 Oct;5(10):2691-700
[
17022640.001
]
[Cites]
World J Gastroenterol. 2006 Dec 21;12(47):7604-12
[
17171788.001
]
[Cites]
Hepatology. 2007 Apr;45(4):948-56
[
17393466.001
]
[Cites]
Anal Bioanal Chem. 2007 Jun;388(3):637-43
[
17447055.001
]
[Cites]
J Cancer Res Clin Oncol. 2007 Nov;133(11):825-34
[
17516088.001
]
[Cites]
Hepatology. 2007 Sep;46(3):649-57
[
17654742.001
]
[Cites]
Nat Clin Pract Gastroenterol Hepatol. 2007 Aug;4(8):432-41
[
17667992.001
]
[Cites]
Clin Chem. 2007 Oct;53(10):1792-9
[
17702858.001
]
[Cites]
Aliment Pharmacol Ther. 2007 Sep 15;26(6):847-58
[
17767469.001
]
[Cites]
J Proteome Res. 2008 Feb;7(2):603-10
[
18189345.001
]
[Cites]
J Exp Clin Cancer Res. 2007 Dec;26(4):505-8
[
18365545.001
]
[Cites]
Hepatology. 2008 Aug;48(2):519-30
[
18571811.001
]
[Cites]
Methods Mol Biol. 2008;484:177-92
[
18592180.001
]
[Cites]
J Viral Hepat. 2009 Jun;16(6):418-29
[
19226329.001
]
[Cites]
J Biol Chem. 2009 Aug 7;284(32):21165-76
[
19531480.001
]
[Cites]
J Viral Hepat. 2010 Nov;17(11):816-24
[
20002297.001
]
[Cites]
Science. 1999 Jul 2;285(5424):110-3
[
10390360.001
]
[Cites]
Nat Biotechnol. 1999 Oct;17(10):994-9
[
10504701.001
]
[Cites]
Cancer. 2000 Feb 1;88(3):544-9
[
10649245.001
]
[Cites]
Am J Gastroenterol. 2000 Apr;95(4):1036-40
[
10763956.001
]
[Cites]
Electrophoresis. 2000 Apr;21(6):1164-77
[
10786889.001
]
[Cites]
Glycobiology. 2001 Apr;11(4):275-81
[
11358876.001
]
[Cites]
Hepatogastroenterology. 2002 Jan-Feb;49(43):235-8
[
11941963.001
]
[Cites]
Mol Cell Proteomics. 2002 Apr;1(4):304-13
[
12096112.001
]
[Cites]
Mol Cell Proteomics. 2002 May;1(5):376-86
[
12118079.001
]
[Cites]
Hepatology. 2003 May;37(5):1114-21
[
12717392.001
]
[Cites]
Proteomics. 2003 May;3(5):666-74
[
12748946.001
]
[Cites]
Rapid Commun Mass Spectrom. 2003;17(14):1642-50
[
12845591.001
]
[Cites]
Mol Cell Proteomics. 2004 Apr;3(4):399-409
[
14726492.001
]
[Cites]
Nat Med. 2004 Apr;10(4):429-34
[
15152612.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84
[
15642945.001
]
[Cites]
J Virol. 2005 Jun;79(12):7558-69
[
15919910.001
]
[Cites]
Proteomics. 2005 Nov;5(17):4581-8
[
16240287.001
]
[Cites]
Br J Cancer. 2006 Jan 30;94(2):287-92
[
16404431.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Jan;4(1):111-7
[
16431313.001
]
[Cites]
J Proteome Res. 2006 Feb;5(2):308-15
[
16457596.001
]
[Cites]
Am J Gastroenterol. 2006 Sep;101(9):2038-43
[
16848811.001
]
[Cites]
Nat Protoc. 2006;1(6):2650-60
[
17406521.001
]
[Cites]
Clin Chem. 2007 Jul;53(7):1254-63
[
17510303.001
]
[Cites]
J Cell Biochem. 2008 Feb 15;103(3):740-52
[
17557278.001
]
[Cites]
Mol Cell Proteomics. 2007 Oct;6(10):1798-808
[
17627933.001
]
[Cites]
Clin Cancer Res. 2008 Jan 15;14(2):470-7
[
18223221.001
]
[Cites]
Proteomics. 2008 Aug;8(16):3257-62
[
18646007.001
]
[Cites]
Mol Cell Proteomics. 2008 Oct;7(10):1998-2018
[
18667411.001
]
[Cites]
Hepatology. 2008 Dec;48(6):1851-63
[
18937283.001
]
[Cites]
Hepatology. 2009 Apr;49(4):1257-66
[
19177598.001
]
[Cites]
Methods Mol Biol. 2009;527:173-90, ix
[
19241013.001
]
[Cites]
Hepatology. 2009 Apr;49(4):1375-84
[
19330863.001
]
[Cites]
J Proteome Res. 2010 Jan;9(1):70-8
[
19522540.001
]
[Cites]
Proteomics. 2009 Jun;9(12):3395-408
[
19562805.001
]
[Cites]
Proteomics. 2009 Aug;9(15):3856-68
[
19639599.001
]
[Cites]
BMC Cancer. 2009;9:271
[
19656391.001
]
[Cites]
Proteomics. 2009 Aug;9(16):3989-99
[
19658107.001
]
[Cites]
Hepatology. 2010 Jan;51(1):111-20
[
19885878.001
]
[Cites]
J Proteome Res. 2010 Jan;9(1):308-18
[
19899825.001
]
[Cites]
Int J Oncol. 2010 Jan;36(1):93-9
[
19956837.001
]
[Cites]
J Gastroenterol. 2010 Apr;45(4):459-67
[
20012107.001
]
[Cites]
J Proteomics. 2010 Jun 16;73(8):1421-32
[
20026004.001
]
(PMID = 21192835.001).
[ISSN]
1477-5956
[Journal-full-title]
Proteome science
[ISO-abbreviation]
Proteome Sci
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC3023778
40.
Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C:
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.
BMC Cancer
; 2007 Oct 12;7:192
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal
carcinoma
.
BACKGROUND: It has recently been shown that NDRG2 mRNA is down-regulated or undetectable in several human cancers and
cancer
cell-lines.
The aim of this study has been to examine NDRG2 mRNA expression in colon
cancer
.
When comparing adenomas/carcinomas with adjacent normal tissue from the same individual, NDRG2 expression levels were significantly reduced in both high-risk adenoma (p < 0.001) and in colorectal
carcinoma
(p < 0.001).
There was a trend for NDRG2 levels to decrease with increasing Dukes'
stage
(p < 0.05).
CONCLUSION: Our results demonstrate that expression of NDRG2 is down-regulated at a late
stage
during colorectal carcinogenesis.
Future studies are needed to address whether NDRG2 down-regulation is a cause or consequence of the progression of colorectal adenomas to
carcinoma
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 1999 May 13;18(19):3004-16
[
10378696.001
]
[Cites]
J Mol Diagn. 2006 May;8(2):193-201
[
16645205.001
]
[Cites]
Anal Biochem. 2000 Feb 15;278(2):175-84
[
10660460.001
]
[Cites]
Proteins. 2002 May 1;47(2):163-8
[
11933063.001
]
[Cites]
Mol Cell Biochem. 2002 Jan;229(1-2):35-44
[
11936845.001
]
[Cites]
Scand J Gastroenterol. 2003 Jun;38(6):635-42
[
12825872.001
]
[Cites]
Int J Cancer. 2003 Sep 1;106(3):342-7
[
12845671.001
]
[Cites]
FEBS Lett. 2003 Oct 23;553(3):413-8
[
14572661.001
]
[Cites]
Neurobiol Dis. 2004 Jun;16(1):48-58
[
15207261.001
]
[Cites]
Mech Dev. 1999 May;83(1-2):39-52
[
10381566.001
]
[Cites]
World J Gastroenterol. 2004 Dec 1;10(23):3518-21
[
15526377.001
]
[Cites]
Biochem Soc Trans. 2005 Aug;33(Pt 4):672-5
[
16042571.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7121-6
[
16103061.001
]
[Cites]
Oncogene. 2006 Jan 5;25(1):111-21
[
16247483.001
]
[Cites]
Cancer Cell. 2006 Mar;9(3):157-73
[
16530701.001
]
[Cites]
J Biol Chem. 2006 Dec 22;281(51):39159-68
[
17050536.001
]
(PMID = 17935612.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / NDRG2 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
[Other-IDs]
NLM/ PMC2099434
41.
Oh JJ, Boctor BN, Jimenez CA, Lopez R, Koegel AK, Taschereau EO, Phan DT, Jacobsen SE, Slamon DJ:
Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus.
Hum Genet
; 2008 Feb;123(1):55-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung
cancer
tumor suppressor locus.
Loss of heterozygosity (LOH) at chromosome 3p21.3 is one of the most prevalent genetic disturbances occurring at the earliest
stage
of tumor development for a wide variety of human cancers, culminated in lung
cancer
.
[MeSH-major]
Carcinoma
, Non-Small-Cell Lung / genetics. Cell Cycle Proteins / genetics. Chromosomes, Human, Pair 3. DNA Methylation. DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Lung Neoplasms / genetics. Promoter Regions, Genetic. RNA-Binding Proteins / genetics. Tumor Suppressor Proteins / genetics
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2002 Sep 13;277(37):33654-63
[
12084718.001
]
[Cites]
Cancer Genet Cytogenet. 2007 Apr 15;174(2):100-10
[
17452250.001
]
[Cites]
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
[
5279523.001
]
[Cites]
Oncogene. 2002 Feb 7;21(7):1048-61
[
11850822.001
]
[Cites]
Cancer Res. 2006 Apr 1;66(7):3419-27
[
16585163.001
]
[Cites]
Biochim Biophys Acta. 2005 Jul 25;1730(1):66-76
[
16005989.001
]
[Cites]
Future Oncol. 2005 Feb;1(1):79-92
[
16555978.001
]
[Cites]
Nat Genet. 2003 Jan;33(1):49-54
[
12469122.001
]
[Cites]
Int J Cancer. 2004 May 10;109(6):839-47
[
15027117.001
]
[Cites]
Blood. 2007 Jul 1;110(1):323-33
[
17360941.001
]
[Cites]
Oncogene. 2007 Nov 15;26(52):7283-301
[
17533367.001
]
[Cites]
Cell Biochem Funct. 2007 Nov-Dec;25(6):643-53
[
16927403.001
]
[Cites]
Ai Zheng. 2007 Jan;26(1):9-14
[
17222360.001
]
[Cites]
Cancer Res. 2004 Sep 15;64(18):6438-43
[
15374952.001
]
[Cites]
Cancer Res. 2002 May 1;62(9):2715-20
[
11980673.001
]
[Cites]
Int J Cancer. 2006 Jul 1;119(1):99-107
[
16432833.001
]
[Cites]
Oncogene. 2002 Oct 7;21(45):6915-35
[
12362274.001
]
[Cites]
Inflamm Bowel Dis. 2000 May;6(2):103-6
[
10833069.001
]
[Cites]
Cancer Res. 2005 Mar 15;65(6):2243-50
[
15781637.001
]
[Cites]
Nat Genet. 2000 Jul;25(3):315-9
[
10888881.001
]
[Cites]
J Biol Chem. 1997 Aug 29;272(35):22322-9
[
9268383.001
]
[Cites]
Blood. 2000 May 15;95(10):3208-13
[
10807790.001
]
[Cites]
Cancer Res. 2000 Nov 1;60(21):6116-33
[
11085536.001
]
[Cites]
Cancer Res. 2005 Sep 1;65(17):7782-9
[
16140946.001
]
[Cites]
Cancer Res. 2004 May 1;64(9):2969-76
[
15126327.001
]
[Cites]
Oncogene. 2003 Jan 30;22(4):615-26
[
12555074.001
]
[Cites]
Histol Histopathol. 2003 Apr;18(2):665-77
[
12647816.001
]
[Cites]
J Cell Biochem. 2005 Jan 1;94(1):5-24
[
15514923.001
]
[Cites]
Anal Biochem. 2005 Aug 15;343(2):347-9
[
15992761.001
]
[Cites]
Cancer Res. 1999 Aug 1;59(15):3730-40
[
10446989.001
]
[Cites]
Cancer Res. 2002 Jun 1;62(11):3207-13
[
12036935.001
]
[Cites]
Int J Cancer. 2005 Jul 10;115(5):684-9
[
15704097.001
]
[Cites]
Oncogene. 2000 Feb 17;19(7):870-7
[
10702795.001
]
(PMID = 18038152.001).
[ISSN]
1432-1203
[Journal-full-title]
Human genetics
[ISO-abbreviation]
Hum. Genet.
[Language]
eng
[Grant]
United States / PHS HHS / / P50C A90388
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / RBM5 protein, human; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Proteins
42.
Beretta G, Furlanetto S, Regazzoni L, Zarrella M, Facino RM:
Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies.
J Pharm Biomed Anal
; 2008 Nov 4;48(3):606-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
HNE is the most abundant and genotoxic product of oxidation of dietary polyunsaturated fatty acids, and is believed to be involved in the early
stage
of colorectal carcinogenesis on account of its genotoxic potential.
These results suggest that EGCG and green tea extract, beside the proposed mechanisms of chemoprevention that target multiple cell-signaling pathways that control cell proliferation and apoptosis in
cancer
cells, can also prevent protein carbonylation in the tumor tissue environment, depending on the pH of the medium surrounding the tissue, the type of tumor, the
stage
of dysregulation of lipid peroxidation and, finally, the
stage
of
carcinoma
development.
Hazardous Substances Data Bank.
Green tea
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18619756.001).
[ISSN]
0731-7085
[Journal-full-title]
Journal of pharmaceutical and biomedical analysis
[ISO-abbreviation]
J Pharm Biomed Anal
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Aldehydes; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea
43.
Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA:
Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.
Mol Cancer
; 2010 Jun 15;9:149
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic
cancer
, an ideal
stage
for early
cancer
detection.
An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic
cancer
, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic
cancer
compared to control samples (p < or = 0.03).
CONCLUSIONS: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic
cancer
progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic
cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
[
11814064.001
]
[Cites]
Clin Sci (Lond). 2010 Jun;118(12):717-25
[
20136634.001
]
[Cites]
Anal Chem. 2002 Oct 15;74(20):5383-92
[
12403597.001
]
[Cites]
Anal Chem. 2003 Sep 1;75(17):4646-58
[
14632076.001
]
[Cites]
Pancreas. 1994 Nov;9(6):741-7
[
7846018.001
]
[Cites]
Mech Dev. 1998 Mar;72(1-2):115-30
[
9533957.001
]
[Cites]
Ann Intern Med. 1999 Aug 17;131(4):247-55
[
10454945.001
]
[Cites]
Mol Cell Proteomics. 2004 Dec;3(12):1154-69
[
15385600.001
]
[Cites]
Mol Cell Proteomics. 2005 Apr;4(4):523-33
[
15684406.001
]
[Cites]
Oncogene. 2005 Oct 6;24(44):6626-36
[
16103885.001
]
[Cites]
Int J Cancer. 2006 Jan 15;118(2):405-11
[
16052519.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):1208-17
[
16424060.001
]
[Cites]
Clin Cancer Res. 2006 Mar 15;12(6):1728-34
[
16551856.001
]
[Cites]
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9
[
16609017.001
]
[Cites]
Histol Histopathol. 2007 Jul;22(7):703-8
[
17455144.001
]
[Cites]
Semin Oncol. 2007 Aug;34(4):303-10
[
17674958.001
]
[Cites]
Prostate Cancer Prostatic Dis. 2007;10(3):293-300
[
17457305.001
]
[Cites]
Curr Opin Gastroenterol. 2007 Sep;23(5):508-14
[
17762556.001
]
[Cites]
J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41
[
18053427.001
]
[Cites]
Cancer Res. 2008 Jan 15;68(2):492-7
[
18199544.001
]
[Cites]
EMBO Rep. 2008 May;9(5):429-34
[
18451766.001
]
[Cites]
Cancer Res. 2008 Oct 1;68(19):7811-8
[
18829536.001
]
[Cites]
Cancer Detect Prev. 2008;32(3):236-50
[
18801625.001
]
[Cites]
Cancer Biol Ther. 2009 Feb;8(4):340-6
[
19106647.001
]
[Cites]
PLoS Med. 2009 Apr 7;6(4):e1000046
[
19360088.001
]
[Cites]
Electrophoresis. 2009 Apr;30(7):1132-44
[
19373808.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5
[
19359471.001
]
[Cites]
Histol Histopathol. 2009 Sep;24(9):1121-8
[
19609859.001
]
[Cites]
Cancer Res. 2002 Mar 15;62(6):1868-75
[
11912167.001
]
(PMID = 20550709.001).
[ISSN]
1476-4598
[Journal-full-title]
Molecular cancer
[ISO-abbreviation]
Mol. Cancer
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
[Other-IDs]
NLM/ PMC2893103
44.
Maw MK, Fujimoto J, Tamaya T:
Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers.
Br J Cancer
; 2008 Nov 18;99(10):1557-63
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
ID-1 histoscores and mRNA levels both significantly (P<0.05) increased in uterine cervical cancers according to clinical
stage
regardless of histopathological type or lymph node metastasis.
[MeSH-major]
Adenocarcinoma / metabolism.
Carcinoma
, Squamous Cell / metabolism. Inhibitor of Differentiation Protein 1 / biosynthesis. Neovascularization, Pathologic / metabolism. Uterine Cervical Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Adv Cancer Res. 1985;43:175-203
[
2581424.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23
[
14555767.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
Nucleic Acids Res. 1994 Mar 11;22(5):749-55
[
8139914.001
]
[Cites]
Cancer Res. 1994 Dec 1;54(23):6065-8
[
7954447.001
]
[Cites]
Cell Growth Differ. 1995 Jul;6(7):837-43
[
7547505.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8
[
14578451.001
]
[Cites]
Cancer J. 2004 Jan-Feb;10(1):27-32
[
15000492.001
]
[Cites]
Br J Cancer. 2004 Mar 22;90(6):1198-203
[
15026801.001
]
[Cites]
Br J Cancer. 1996 Apr;73(8):884-8
[
8611421.001
]
[Cites]
Mol Cell Biol. 1997 Dec;17(12):7317-27
[
9372963.001
]
[Cites]
Mol Cell Biol. 1998 Apr;18(4):2371-81
[
9528806.001
]
[Cites]
Mol Cell Biol. 1998 Aug;18(8):4577-88
[
9671467.001
]
[Cites]
Trends Cell Biol. 1998 Feb;8(2):58-65
[
9695810.001
]
[Cites]
EMBO J. 1999 Feb 15;18(4):968-76
[
10022839.001
]
[Cites]
Br J Cancer. 1999 Mar;79(7-8):1249-54
[
10098767.001
]
[Cites]
Br J Cancer. 1999 May;80(5-6):827-33
[
10360662.001
]
[Cites]
Cancer Res. 1999 Jul 1;59(13):3041-4
[
10397240.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41
[
10449746.001
]
[Cites]
Am J Pathol. 1999 Sep;155(3):815-22
[
10487839.001
]
[Cites]
Br J Cancer. 2005 Oct 17;93(8):933-8
[
16189525.001
]
[Cites]
Gynecol Oncol. 2006 Oct;103(1):186-9
[
16595146.001
]
[Cites]
Cancer Lett. 2006 Dec 8;244(2):203-10
[
16469432.001
]
[Cites]
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
[
3893381.001
]
[Cites]
Nature. 1999 Oct 14;401(6754):670-7
[
10537105.001
]
[Cites]
Cancer Res. 2000 Mar 1;60(5):1332-40
[
10728695.001
]
[Cites]
Cancer Res. 2000 Jul 1;60(13):3662-5
[
10910083.001
]
[Cites]
Nature. 2000 Oct 5;407(6804):592-8
[
11034201.001
]
[Cites]
J Cell Sci. 2000 Nov;113 ( Pt 22):3897-905
[
11058077.001
]
[Cites]
Cancer Res. 2000 Nov 1;60(21):5929-33
[
11085505.001
]
[Cites]
Nature. 2001 Feb 22;409(6823):1067-70
[
11234019.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6
[
11427735.001
]
[Cites]
Cancer Res. 2001 Aug 1;61(15):5703-6
[
11479201.001
]
[Cites]
Cancer Res. 2001 Aug 15;61(16):6008-11
[
11507043.001
]
[Cites]
Nat Med. 2001 Nov;7(11):1194-201
[
11689883.001
]
[Cites]
Cancer. 2001 Nov 15;92(10):2569-77
[
11745191.001
]
[Cites]
Oncogene. 2002 Mar 14;21(12):1812-22
[
11896613.001
]
[Cites]
J Urol. 2002 Jun;167(6):2598-602
[
11992094.001
]
[Cites]
Carcinogenesis. 2002 May;23(5):721-5
[
12016143.001
]
[Cites]
Mol Carcinog. 2002 Sep;35(1):42-9
[
12203366.001
]
[Cites]
Ann Oncol. 2002 Oct;13(10):1598-604
[
12377648.001
]
[Cites]
Cancer Cell. 2002 Dec;2(6):473-83
[
12498716.001
]
[Cites]
Clin Cancer Res. 2003 Feb;9(2):779-85
[
12576450.001
]
[Cites]
Int J Cancer. 2003 May 10;104(6):677-82
[
12640673.001
]
[Cites]
Oncogene. 2003 Jul 17;22(29):4498-508
[
12881706.001
]
[Cites]
J Pathol. 2003 Aug;200(5):561-7
[
12898591.001
]
[ErratumIn]
Br J Cancer. 2009 Jul 21;101(2):377-8
(PMID = 19002177.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Angiogenesis Modulating Agents; 0 / Biomarkers, Tumor; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger
[Other-IDs]
NLM/ PMC2584935
45.
Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M:
Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
Ann Surg Oncol
; 2005 Feb;12(2):111-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Relationship between pathologic T-
stage
and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal
cancer
.
BACKGROUND: We investigated the relationship between pathologic T-
stage
and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical
stage
II to III rectal
carcinoma
.
METHODS: The records of consecutive patients with clinical
stage
II to III
carcinoma
of the mid or low rectum who underwent surgery after CRT were reviewed.
Indications for preoperative CRT were
cancer
up to 11 cm from the
anal
verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis
stage
II or III.
The pretreatment tumor-node-metastasis
stage
was as follows: I, n = 1; II, n = 96; and III, n = 138.
According to the pT
stage
, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
On considering pT
stage
alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical
stage
II to III mid or low rectal
cancer
, the risk of nodal metastases is very low.
Genetic Alliance.
consumer health - Rectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Ann Surg Oncol. 2005 Feb;12(2):95-7
[
15827785.001
]
(PMID = 15827790.001).
[ISSN]
1068-9265
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
46.
Zheng W, Armes JE, Slavin J, Zhu Y, Ni C:
Preliminary comparison of tumor biologic factors in breast carcinomas from Australian and Chinese women.
Anal Quant Cytol Histol
; 2010 Jun;32(3):155-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
STUDY DESIGN: Three hundred cases of breast carcinomas were assessed for histologic and immunophenotypic characteristics from the pathology archives of the Changhai and
St
. Vincent's Hospitals.
CONCLUSION: This study indicates that both inherent tumor biology and
stage
at presentation influence adversely affect the outcome of breast
carcinoma
in Chinese compared as with Australian women.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20701069.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CCND1 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
47.
Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA:
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Int J Radiat Oncol Biol Phys
; 2010 Nov 15;78(4):1064-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Squamous cell
carcinoma
of the
anal
canal
: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
PURPOSE: Intensity-modulated radiation treatment (IMRT) is increasingly used in the treatment of squamous cell
carcinoma
of the
anal
canal
(SCCAC).
In patients with advanced tumor or nodal
stage
, common iliac nodes should also be included in the CTV.
[MeSH-major]
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Tumor Burden
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 20350793.001).
[ISSN]
1879-355X
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
48.
Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP:
Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis.
Electrophoresis
; 2010 Jan;31(4):599-610
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of candidate biomarkers in ovarian
cancer
serum by depletion of highly abundant proteins and differential in-gel electrophoresis.
Ovarian
cancer
is the fifth leading cause
of cancer
death for women in the US, yet survival rates are over 90% when it is diagnosed at an early
stage
, highlighting the need for biomarkers for early detection.
To enhance the discovery of tumor-specific proteins that could represent novel serum biomarkers for ovarian
cancer
, we depleted serum of highly abundant proteins which can mask the detection of proteins present in serum at low concentrations.
Three commercial immunoaffinity columns were used in parallel to deplete the highly abundant proteins in serum from 60 patients with serous ovarian
carcinoma
and 60 non-
cancer
controls.
The number of protein spots that were elevated in ovarian
cancer
sera by at least twofold ranged from 36 to 248, depending upon the depletion and separation methods.
From the 33 spots picked for MS analysis, nine different proteins were identified, including the novel candidate ovarian
cancer
biomarkers leucine-rich alpha2 glycoprotein-1 and ficolin 3.
Western blotting validated the relative increases in serum protein levels for three of the proteins identified, demonstrating the utility of this approach for the identification of novel serum biomarkers for ovarian
cancer
.
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Electrophoresis. 2002 Sep;23(18):3168-81
[
12298089.001
]
[Cites]
Anal Chem. 2002 Apr 15;74(8):1779-91
[
11985308.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):2904-11
[
12912935.001
]
[Cites]
Anal Chem. 2003 Sep 1;75(17):4646-58
[
14632076.001
]
[Cites]
Mol Cell Proteomics. 2004 Apr;3(4):355-66
[
14764655.001
]
[Cites]
Br J Cancer. 2004 Jul 5;91(1):129-40
[
15199385.001
]
[Cites]
Proteomics. 2004 Aug;4(8):2476-95
[
15274142.001
]
[Cites]
Cancer Res. 2004 Aug 15;64(16):5882-90
[
15313933.001
]
[Cites]
Obstet Gynecol. 1971 Sep;38(3):427-35
[
4999312.001
]
[Cites]
N Engl J Med. 1983 Oct 13;309(15):883-7
[
6310399.001
]
[Cites]
Int J Cancer. 1988 Nov 15;42(5):677-80
[
3182103.001
]
[Cites]
Anal Chem. 1996 Mar 1;68(5):850-8
[
8779443.001
]
[Cites]
Electrophoresis. 1996 Mar;17(3):612-6
[
8740187.001
]
[Cites]
Crit Rev Immunol. 1995;15(3-4):201-14
[
8834448.001
]
[Cites]
Arch Biochem Biophys. 1998 Dec 15;360(2):223-32
[
9851834.001
]
[Cites]
Nat Rev Cancer. 2004 Nov;4(11):876-90
[
15516960.001
]
[Cites]
Clin Chem. 2005 Oct;51(10):1933-45
[
16099937.001
]
[Cites]
J Proteome Res. 2005 Sep-Oct;4(5):1742-51
[
16212428.001
]
[Cites]
Proteomics. 2005 Nov;5(17):4625-36
[
16220531.001
]
[Cites]
Proteomics. 2006 Jun;6(11):3236-42
[
16645986.001
]
[Cites]
J Proteome Res. 2006 Jun;5(6):1379-87
[
16739989.001
]
[Cites]
Proteomics. 2006 Jul;6(13):3938-48
[
16767791.001
]
[Cites]
Mol Cell Proteomics. 2006 Nov;5(11):2167-74
[
16854842.001
]
[Cites]
J Proteome Res. 2006 Dec;5(12):3318-25
[
17137333.001
]
[Cites]
Mol Cell Proteomics. 2007 Jan;6(1):64-71
[
17030953.001
]
[Cites]
Neoplasia. 2007 Jan;9(1):1-7
[
17325738.001
]
[Cites]
J Proteome Res. 2007 Apr;6(4):1440-50
[
17315909.001
]
[Cites]
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):257-67
[
17303479.001
]
[Cites]
J Proteome Res. 2007 Aug;6(8):2936-62
[
17583933.001
]
[Cites]
Electrophoresis. 2007 Dec;28(23):4302-10
[
18041032.001
]
[Cites]
Clin Cancer Res. 2007 Dec 15;13(24):7370-9
[
18094419.001
]
[Cites]
J Proteome Res. 2008 Jan;7(1):339-51
[
18076136.001
]
[Cites]
Mol Immunol. 2008 Mar;45(6):1623-32
[
18006063.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
J Immunol Methods. 2008 Jul 20;336(1):22-9
[
18436231.001
]
[Cites]
PLoS One. 2008;3(6):e2425
[
18560578.001
]
[Cites]
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):591-9
[
17944921.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81
[
18843033.001
]
[Cites]
Fertil Steril. 2008 Sep;90(3):761-8
[
17583700.001
]
[Cites]
PLoS Med. 2008 Dec 2;5(12):e232
[
19053170.001
]
[Cites]
Arch Gynecol Obstet. 2009 Mar;279(3):365-71
[
18665377.001
]
[Cites]
J Proteome Res. 2009 Feb;8(2):942-57
[
19093873.001
]
[Cites]
Crit Rev Clin Lab Sci. 2007;44(1):87-114
[
17175521.001
]
[Cites]
Cancer Treat Res. 2002;107:61-97
[
11775462.001
]
[Cites]
Proteomics. 2002 Jan;2(1):76-84
[
11788994.001
]
[Cites]
Anal Chem. 2002 Oct 15;74(20):5383-92
[
12403597.001
]
(PMID = 20162585.001).
[ISSN]
1522-2683
[Journal-full-title]
Electrophoresis
[ISO-abbreviation]
Electrophoresis
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA106878-04; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-04; United States / NCI NIH HHS / CA / R01CA106878; United States / PHS HHS / / RRR15808
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / IgY; 0 / Immunoglobulins
[Other-IDs]
NLM/ NIHMS264126; NLM/ PMC3520508
49.
Brunner A, Schönhuber G, Waldner M, Schaefer G, Mikuz G, Verdorfer I:
Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system.
Anal Quant Cytol Histol
; 2008 Oct;30(5):297-305
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chromosomal aberrations in urothelial
carcinoma
of the bladder and the World Health Organization 2004 grading system.
OBJECTIVE: To evaluate differences in chromosomal aberrations in recurrent urothelial
cancer
(UC) of the bladder between the World Health Organization (WHO) 1973 and 2004 classification a retrospective study was performed.
Grade 2 tumors, reclassified as high-grade tumors, were of higher
stage
and showed aberrations usually associated with higher grade and poor outcome (1p+, 16p+, -2 and -5q).
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18980162.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
50.
Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF:
Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
Radiat Oncol
; 2006;1:29
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Local tumor control and toxicity in HIV-associated
anal carcinoma
treated with radiotherapy in the era of antiretroviral therapy.
PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with
anal
cancer
treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
10 TNM-
stage
and age matched HIV-seronegative patients (1992-2003) were compared with the 10 HIV-seropositive patients.
Pattern of care, local disease control (LC), overall survival (OS),
cancer
-specific survival (CSS), and toxicity were assessed.
[MeSH-major]
Antiretroviral Therapy, Highly Active.
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy.
Anus
Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
HIV InSite.
treatment guidelines - Adherence to HIV Antiretroviral Therapy
.
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1499-508
[
10580400.001
]
[Cites]
Radiology. 1994 Oct;193(1):251-4
[
8090901.001
]
[Cites]
Eur J Cancer. 2000 Apr;36(6):754-8
[
10762748.001
]
[Cites]
Semin Oncol. 2000 Aug;27(4):390-401
[
10950365.001
]
[Cites]
AIDS. 2000 Sep 8;14(13):1921-33
[
10997396.001
]
[Cites]
J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):150-6
[
11103045.001
]
[Cites]
Dis Colon Rectum. 2001 Apr;44(4):506-12
[
11330577.001
]
[Cites]
Dis Colon Rectum. 2001 Oct;44(10):1496-502
[
11598480.001
]
[Cites]
AIDS. 2001 Dec 7;15(18):2371-8
[
11740187.001
]
[Cites]
Gastroenterol Clin Biol. 2002 Feb;26(2):150-6
[
11938066.001
]
[Cites]
AIDS. 2002 Jun 14;16(9):1251-6
[
12045490.001
]
[Cites]
Cancer Res. 2002 Sep 15;62(18):5230-5
[
12234989.001
]
[Cites]
Eur J Cancer. 2003 Jan;39(1):45-51
[
12504657.001
]
[Cites]
Ann Intern Med. 2003 Mar 18;138(6):453-9
[
12639077.001
]
[Cites]
Clin Exp Immunol. 2003 Oct;134(1):98-106
[
12974761.001
]
[Cites]
Br J Cancer. 2003 Dec 1;89(11):2057-61
[
14647138.001
]
[Cites]
Antivir Ther. 2004 Feb;9(1):13-22
[
15040532.001
]
[Cites]
AIDS. 2004 Feb 20;18(3):485-93
[
15090801.001
]
[Cites]
AIDS. 2004 Mar 5;18(4):673-81
[
15090773.001
]
[Cites]
Int J STD AIDS. 2004 May;15(5):348-51
[
15117507.001
]
[Cites]
Dis Colon Rectum. 2004 Aug;47(8):1305-9
[
15484343.001
]
[Cites]
Am J Surg. 1979 Feb;137(2):228-30
[
106741.001
]
[Cites]
Curr Probl Cancer. 1980 Jun;4(12):1-44
[
7408530.001
]
[Cites]
Cancer. 1984 Jul 1;54(1):114-25
[
6326995.001
]
[Cites]
Am J Surg. 1985 Jan;149(1):95-101
[
3966647.001
]
[Cites]
Dis Colon Rectum. 1987 Jun;30(6):444-8
[
3595363.001
]
[Cites]
J Clin Oncol. 1996 Sep;14(9):2527-39
[
8823332.001
]
[Cites]
Lancet. 1996 Oct 19;348(9034):1049-54
[
8874455.001
]
[Cites]
Clin Oncol (R Coll Radiol). 1996;8(5):319-22
[
8934052.001
]
[Cites]
J Clin Oncol. 1997 May;15(5):2040-9
[
9164216.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5
[
9169819.001
]
[Cites]
Science. 1997 Jul 4;277(5322):112-6
[
9204894.001
]
[Cites]
Cancer. 1997 Aug 15;80(4):805-15
[
9264365.001
]
[Cites]
Acta Oncol. 1997;36(8):799-802
[
9482685.001
]
[Cites]
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9
[
9525431.001
]
[Cites]
Med Oncol. 1998 Apr;15(1):50-7
[
9643531.001
]
[Cites]
J Natl Cancer Inst Monogr. 1998;(23):15-20
[
9709296.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Jan;84(1):145-50
[
9920075.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31
[
10219805.001
]
[Cites]
J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8
[
10430218.001
]
[Cites]
Neurology. 1999 Sep 11;53(4):782-9
[
10489041.001
]
[Cites]
AIDS. 1999 Oct 1;13(14):1913-20
[
10513650.001
]
[Cites]
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5
[
15577408.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102
[
15629599.001
]
[Cites]
Clin Pharmacokinet. 2005;44(2):111-45
[
15656694.001
]
[Cites]
Dis Colon Rectum. 2005 Jun;48(6):1176-81
[
15906137.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1988 Feb;14(2):253-9
[
3338946.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1161-9
[
2599904.001
]
[Cites]
Int J Colorectal Dis. 1989 Dec;4(4):234-43
[
2614221.001
]
[Cites]
Histopathology. 1990 Jun;16(6):545-55
[
2376397.001
]
[Cites]
Cancer Res. 1991 Feb 1;51(3):1014-9
[
1846314.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):575-80
[
1995543.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25
[
1938508.001
]
[Cites]
Lancet. 1994 Mar 12;343(8898):636-9
[
7906812.001
]
[Cites]
Dis Colon Rectum. 1994 Sep;37(9):861-5
[
8076484.001
]
[Cites]
Pediatrics. 1999 Dec;104(6):1394-6
[
10585995.001
]
(PMID = 16916475.001).
[ISSN]
1748-717X
[Journal-full-title]
Radiation oncology (London, England)
[ISO-abbreviation]
Radiat Oncol
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC1570351
[General-notes]
NLM/ Original DateCompleted: 20070726
51.
Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH:
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
J Thorac Oncol
; 2008 Sep;3(9):1018-25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung
cancer
in patients at least 70 years old: a wisconsin oncology network study.
INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung
cancer
(NSCLC).
METHODS: Chemotherapy-naive patients >/=70-years-old with
stage
IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.
Genetic Alliance.
consumer health - Lung Cancer
.
Genetic Alliance.
consumer health - Non-small cell lung cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
VINORELBINE
.
Hazardous Substances Data Bank.
VINBLASTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1999 Dec 15;59(24):6178-84
[
10626810.001
]
[Cites]
Oncologist. 2007 Dec;12(12):1416-24
[
18165618.001
]
[Cites]
Cancer. 2000 Jun 15;88(12):2677-85
[
10870049.001
]
[Cites]
Cancer Res. 2000 Jul 1;60(13):3338-42
[
10910034.001
]
[Cites]
Clin Cancer Res. 2000 Jul;6(7):2690-5
[
10914711.001
]
[Cites]
Clin Cancer Res. 2000 Oct;6(10):4136-41
[
11051267.001
]
[Cites]
Oncologist. 2001;6 Suppl 1:4-7
[
11181997.001
]
[Cites]
J Clin Oncol. 2002 Jan 15;20(2):494-502
[
11786579.001
]
[Cites]
Clin Cancer Res. 2002 Mar;8(3):904-12
[
11895925.001
]
[Cites]
Mol Cancer Ther. 2003 May;2(5):479-88
[
12748310.001
]
[Cites]
Eur J Cancer. 2003 Nov;39(16):2264-72
[
14556916.001
]
[Cites]
J Am Geriatr Soc. 1968 May;16(5):622-6
[
5646906.001
]
[Cites]
Am J Clin Oncol. 1982 Dec;5(6):649-55
[
7165009.001
]
[Cites]
Clin Pharmacol Ther. 1985 Aug;38(2):228-34
[
4017423.001
]
[Cites]
Clin Pharmacol Ther. 1985 Oct;38(4):387-93
[
4042521.001
]
[Cites]
J Chronic Dis. 1987;40(5):373-83
[
3558716.001
]
[Cites]
J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20
[
8833984.001
]
[Cites]
Eur J Cancer. 1997 Feb;33(2):301-3
[
9135505.001
]
[Cites]
Eur J Cancer. 1997 Mar;33(3):392-7
[
9155522.001
]
[Cites]
Cancer Res. 1997 Jun 15;57(12):2452-9
[
9192825.001
]
[Cites]
Eur J Cancer. 1998 Jul;34(8):1250-9
[
9849488.001
]
[Cites]
J Clin Oncol. 2005 Apr 20;23(12):2831-9
[
15837997.001
]
[Cites]
J Clin Oncol. 2005 May 1;23(13):3125-37
[
15860872.001
]
[Cites]
Clin Lung Cancer. 2005 May;6(6):361-6
[
15943897.001
]
[Cites]
J Clin Oncol. 2005 Sep 1;23(25):5892-9
[
16043829.001
]
[Cites]
Cancer. 2005 Nov 1;104(9):1998-2005
[
16206252.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3187-205
[
16682719.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2433-53
[
16750358.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Cancer Control. 2007 Jan;14(1):32-43
[
17242669.001
]
[Cites]
J Thorac Oncol. 2006 Mar;1(3):218-25
[
17409860.001
]
[Cites]
J Thorac Oncol. 2006 Sep;1(7):673-8
[
17409935.001
]
[Cites]
J Clin Oncol. 2007 May 10;25(14):1824-31
[
17488980.001
]
[Cites]
J Thorac Oncol. 2007 Oct;2(10):933-8
[
17909356.001
]
[Cites]
J Clin Oncol. 2007 Dec 1;25(34):5381-9
[
18048819.001
]
[Cites]
Clin Cancer Res. 2000 Jan;6(1):78-89
[
10656435.001
]
(PMID = 18758305.001).
[ISSN]
1556-1380
[Journal-full-title]
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
[ISO-abbreviation]
J Thorac Oncol
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
[Publication-type]
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
[Other-IDs]
NLM/ NIHMS52764; NLM/ PMC2562273
52.
Alvarez G, Perry A, Tan BR, Wang HL:
Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification.
Mod Pathol
; 2006 Jul;19(7):942-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of epidermal growth factor receptor in squamous cell carcinomas of the
anal
canal
is independent of gene amplification.
The EGFR status in squamous cell
carcinoma
of the
anal
canal
, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated.
In this study, 38 primary squamous cell carcinomas of the
anal
canal
were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers.
There were no significant differences among tumors stratified by
stage
, degree of keratinization, or tissue block storage times.
These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the
anal
canal
through mechanisms other than gene amplification.
[MeSH-major]
Anus
Neoplasms / metabolism.
Carcinoma
, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / metabolism. Up-Regulation
MedlinePlus Health Information.
consumer health - Anal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16648870.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 2.7.10.1 / Receptor, Epidermal Growth Factor
53.
Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA:
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
Dis Colon Rectum
; 2008 Nov;51(11):1641-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal
carcinoma
: a pilot study.
METHODS: Patients with locally invasive (T2-4) primary or node-positive rectal
cancer
located <12 cm from the
anal
verge were recruited for this pilot study.
Pretreatment tumor size and
stage
were determined by endorectal ultrasonography, CT, and magnetic resonance imaging.
CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal
cancer
.
[MeSH-major]
Carcinoma
/ diagnosis.
Carcinoma
/ therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18682881.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R24 CA086307
[Publication-type]
Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
[Other-IDs]
NLM/ NIHMS802312; NLM/ PMC4962601
54.
Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH, Zhong D, Zhou W:
Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer.
Breast Cancer Res
; 2005;7(6):R1051-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early
stage
, node-negative breast
cancer
.
INTRODUCTION: Identification of breast
cancer
patients at risk for postoperative distant relapse is an important clinical issue.
METHODS: Using 'counting alleles', a novel experimental method, we determined allelic status of chromosomes 8p and 18q in a case-control study with 65 early
stage
, node negative, invasive ductal carcinomas (IDCs).
CONCLUSION: Our finding suggests that differential allelic loss of chromosomes 8p and 18q may represent subtypes of early
stage
IDC with different tumor progression behaviors.
[MeSH-major]
Allelic Imbalance. Breast Neoplasms / genetics.
Carcinoma
, Ductal, Breast / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 8 / genetics
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2002 Jan 31;415(6871):484-5
[
11831227.001
]
[Cites]
Lancet. 2002 Jan 19;359(9302):219-25
[
11812558.001
]
[Cites]
Clin Cancer Res. 2002 Dec;8(12):3863-9
[
12473601.001
]
[Cites]
Curr Opin Oncol. 2003 Jan;15(1):50-4
[
12490761.001
]
[Cites]
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
[
14974761.001
]
[Cites]
Prostate. 2004 Sep 15;61(1):81-91
[
15287096.001
]
[Cites]
Cancer Res. 1996 Jun 1;56(11):2527-30
[
8653691.001
]
[Cites]
J Mol Med (Berl). 1997 Jun;75(6):429-39
[
9231883.001
]
[Cites]
Nat Biotechnol. 1998 Jan;16(1):49-53
[
9447593.001
]
[Cites]
Anticancer Res. 1998 Mar-Apr;18(2A):1031-6
[
9615760.001
]
[Cites]
Nat Biotechnol. 1996 Mar;14(3):303-8
[
9630890.001
]
[Cites]
Genet Anal. 1999 Feb;14(5-6):151-6
[
10084107.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
[
10430926.001
]
[Cites]
Breast Cancer Res. 2004;6(6):229-39
[
15535852.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):854-7
[
10706093.001
]
[Cites]
Int J Cancer. 2000 May 20;89(3):305-10
[
10861509.001
]
[Cites]
Nat Biotechnol. 2001 Jan;19(1):78-81
[
11135558.001
]
[Cites]
Cancer Res. 2001 Feb 1;61(3):818-22
[
11221861.001
]
[Cites]
J Pathol. 2001 Apr;193(4):442-9
[
11276002.001
]
[Cites]
Curr Opin Oncol. 2002 Jan;14(1):65-72
[
11790983.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13647-52
[
12370419.001
]
(PMID = 16457686.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC1410773
55.
Lunny DP, Weed E, Nolan PM, Marquardt A, Augustin M, Porter RM:
Mutations in gasdermin 3 cause aberrant differentiation of the hair follicle and sebaceous gland.
J Invest Dermatol
; 2005 Mar;124(3):615-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Defolliculated (Dfl) is a spontaneous mouse mutant with a hair-loss phenotype that includes altered sebaceous gland differentiation, short hair shafts, aberrant catagen
stage
of the hair cycle, and eventual loss of the hair follicle.
Immunohistochemical analysis revealed that gasdermins are expressed specifically in cells at advanced stages of differentiation in the upper epidermis, the differentiating inner root sheath and hair shaft and in the most mature sebocytes of the sebaceous gland and preputial, meibomium, ceruminous gland, and
anal
glands.
[MeSH-minor]
Animals. Antibodies. Antibody Specificity. Base Sequence.
Carcinoma
, Squamous Cell. Cell Differentiation. Cell Line, Tumor. Humans. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Mutant Strains. Molecular Sequence Data. Phenotype. Skin Neoplasms
COS Scholar Universe.
author profiles
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15737203.001).
[ISSN]
0022-202X
[Journal-full-title]
The Journal of investigative dermatology
[ISO-abbreviation]
J. Invest. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies; 0 / Gsdma3 protein, mouse; 0 / Proteins
56.
de Bree E, van Ruth S, Dewit LG, Zoetmulder FA:
High risk of colostomy with primary radiotherapy for anal cancer.
Ann Surg Oncol
; 2007 Jan;14(1):100-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High risk of colostomy with primary radiotherapy for
anal
cancer
.
BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for
anal
cancer
in an effort to avoid colostomy.
Early
stage
disease, low T-score and absence of infiltration in adjacent organs were associated with a reduced need for colostomy in univariate analysis.
CONCLUSIONS: In approximately one-third of the patients treated by
anal
sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for
anal
cancer
.
[MeSH-major]
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / radiotherapy. Colostomy
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17066231.001).
[ISSN]
1068-9265
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
57.
Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H:
[Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
Gan To Kagaku Ryoho
; 2007 Nov;34(12):2050-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Squamous cell
carcinoma
of the
anal
canal
showing complete response following chemoradiotherapy--a case report].
We report a case of squamous cell
carcinoma
of the
anal
canal
which showed complete response following chemoradiotherapy.
A 54-year-old woman was diagnosed as having squamous cell
carcinoma
of the
anal
canal
(T2N0M0
stage
II).
This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell
carcinoma
of the
anal
canal
.
[MeSH-major]
Anus
Neoplasms / drug therapy.
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / drug therapy.
Carcinoma
, Squamous Cell / radiotherapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18219895.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
58.
Hauerstock D, Ennis RD, Grossbard M, Evans A:
Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
Clin Colorectal Cancer
; 2010 Oct;9(4):238-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy and toxicity of chemoradiation in the treatment of HIV-associated
anal
cancer
.
PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell
carcinoma
of the
anal
canal
in HIV-positive patients treated at a single institution.
PATIENTS AND METHODS: HIV-positive patients with squamous cell
carcinoma
of the
canal
treated at Continuum
Cancer
Centers-affiliated hospitals were identified from tumor registries.
We reviewed hospital and treatment charts to gather data relating to demographics, HIV status including cluster of differentiation 4 (CD4) count and viral load, tumor
stage
, radiation and chemotherapy treatment, toxicity and local control, and survival.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Anus
Neoplasms / therapy.
Carcinoma
, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal
Genetic Alliance.
consumer health - Anal Cancer
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
MITOMYCIN C
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20920996.001).
[ISSN]
1938-0674
[Journal-full-title]
Clinical colorectal cancer
[ISO-abbreviation]
Clin Colorectal Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
59.
Chen Y, Lim BK, Hashim OH:
Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.
J Hematol Oncol
; 2009;2:37
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Different altered
stage
correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian
carcinoma
.
BACKGROUND: The general enhanced expression of alpha1-antichymotrypsin (ACT), clusterin (CLU), alpha1-antitrypsin (AAT), haptoglobin beta-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian
carcinoma
(EOCa) was recently reported.
In the present study, we compared the expression of the serum acute-phase proteins (APPs) in the patients according to their stages
of cancer
.
RESULTS: Different altered
stage
correlative expression of the high abundance serum APPs was demonstrated in sera of the patients studied.
While the expression of ACT, HAP and AAT appeared to demonstrate positive correlation with the three initial stages of the
cancer
, inverse correlation was apparently detected in the expression of LRG and CLU.
For patients who were diagnosed with
stage
IV of the
cancer
, expression of the serum APPs did not conform to the altered progression changes.
[MeSH-major]
Acute-Phase Proteins / metabolism.
Carcinoma
in Situ / blood. Ovarian Neoplasms / blood
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17039-44
[
15572443.001
]
[Cites]
Gene Ther. 1999 Sep;6(9):1512-9
[
10490760.001
]
[Cites]
J Proteome Res. 2005 Sep-Oct;4(5):1742-51
[
16212428.001
]
[Cites]
Exp Oncol. 2005 Sep;27(3):233-7
[
16244588.001
]
[Cites]
Proteomics. 2005 Nov;5(16):4287-95
[
16254924.001
]
[Cites]
J Med Invest. 2006 Feb;53(1-2):20-8
[
16537992.001
]
[Cites]
Proteomics. 2006 Jul;6(13):3938-48
[
16767791.001
]
[Cites]
Neoplasma. 2007;54(1):46-50
[
17203891.001
]
[Cites]
Neoplasia. 2007 Jan;9(1):1-7
[
17325738.001
]
[Cites]
Front Biosci. 2007;12:2821-35
[
17485262.001
]
[Cites]
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):257-67
[
17303479.001
]
[Cites]
Electrophoresis. 2007 Jun;28(12):1989-96
[
17503403.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1845-51
[
17855704.001
]
[Cites]
Proteomics. 2007 Dec;7(23):4292-302
[
17963278.001
]
[Cites]
Electrophoresis. 2008 Jun;29(12):2645-50
[
18494030.001
]
[Cites]
Eur J Gynaecol Oncol. 2008;29(6):617-9
[
19115690.001
]
[Cites]
Cancer Res. 2000 Jan 1;60(1):170-6
[
10646870.001
]
[Cites]
Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5
[
12144685.001
]
[Cites]
Technol Cancer Res Treat. 2002 Aug;1(4):263-72
[
12625785.001
]
[Cites]
Urology. 2003 Nov;62(5 Suppl 1):27-33
[
14607215.001
]
[Cites]
Anticancer Res. 2004 Jan-Feb;24(1):241-7
[
15015603.001
]
[Cites]
Ann N Y Acad Sci. 2004 Jun;1019:206-10
[
15247015.001
]
[Cites]
Electrophoresis. 2004 Jul;25(14):2392-401
[
15274022.001
]
[Cites]
N Engl J Med. 1983 Oct 13;309(15):883-7
[
6310399.001
]
[Cites]
Electrophoresis. 1988 Jan;9(1):28-32
[
2466645.001
]
[Cites]
Hum Reprod. 1989 Jan;4(1):1-12
[
2651469.001
]
[Cites]
J Clin Lab Anal. 1995;9(2):123-8
[
7536238.001
]
[Cites]
Anal Chem. 1996 Mar 1;68(5):850-8
[
8779443.001
]
[Cites]
Electrophoresis. 1996 Mar;17(3):612-6
[
8740187.001
]
[Cites]
Kidney Int. 1998 Jun;53(6):1647-53
[
9607196.001
]
[Cites]
Clin Cancer Res. 2005 Feb 1;11(3):1110-8
[
15709178.001
]
(PMID = 19709441.001).
[ISSN]
1756-8722
[Journal-full-title]
Journal of hematology & oncology
[ISO-abbreviation]
J Hematol Oncol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Acute-Phase Proteins
[Other-IDs]
NLM/ PMC2739531
60.
Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC:
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Gynecol Oncol
; 2008 Mar;108(3):619-26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Folate receptor alpha as a tumor target in epithelial ovarian
cancer
.
FRalpha staining was analyzed in light of disease morphology,
stage
, grade, debulking status, and time from diagnosis to recurrence and death.
CONCLUSION: FRalpha expression occurs frequently, especially in the common high-grade, high-
stage
serous tumors that are most likely to recur.
New findings from this study show that FRalpha expression is maintained on metastatic foci and recurrent tumors, suggesting that novel folate-targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian
cancer
.
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Ovarian epithelial cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Nucl Med. 2003 May;44(5):700-7
[
12732670.001
]
[Cites]
Gynecol Oncol. 2007 Oct;107(1):52-7
[
17582475.001
]
[Cites]
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1085-97
[
15094208.001
]
[Cites]
Adv Drug Deliv Rev. 2004 Apr 29;56(8):1219-31
[
15094217.001
]
[Cites]
Am J Physiol Cell Physiol. 2004 Aug;287(2):C517-26
[
15102609.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6
[
2062838.001
]
[Cites]
Cancer Res. 1991 Oct 1;51(19):5329-38
[
1717147.001
]
[Cites]
Cancer Res. 1992 Jun 15;52(12):3396-401
[
1596899.001
]
[Cites]
Cancer Res. 1993 Dec 1;53(23):5791-6
[
8242637.001
]
[Cites]
Cancer. 1994 May 1;73(9):2432-43
[
7513252.001
]
[Cites]
Int J Cancer Suppl. 1994;8:89-95
[
8194901.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61
[
7568072.001
]
[Cites]
APMIS. 1995 Sep;103(9):663-70
[
7488388.001
]
[Cites]
Int J Cancer. 1998 Apr 17;79(2):121-6
[
9583724.001
]
[Cites]
Arch Biochem Biophys. 1999 Jun 15;366(2):183-91
[
10356282.001
]
[Cites]
N Engl J Med. 2004 Dec 9;351(24):2519-29
[
15590954.001
]
[Cites]
Mol Cancer Ther. 2004 Dec;3(12):1505-12
[
15634643.001
]
[Cites]
Anal Biochem. 2005 Mar 15;338(2):284-93
[
15745749.001
]
[Cites]
Curr Pharm Biotechnol. 2005 Apr;6(2):131-50
[
15853692.001
]
[Cites]
J Pharm Sci. 2005 Oct;94(10):2135-46
[
16136558.001
]
[Cites]
Front Biosci. 2006;11:506-19
[
16146749.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2168-72
[
16172227.001
]
[Cites]
Curr Oncol Rep. 2005 Nov;7(6):451-8
[
16221382.001
]
[Cites]
Cancer Biother Radiopharm. 2006 Feb;21(1):49-60
[
16480331.001
]
[Cites]
Cancer. 2006 May 1;106(9):1933-9
[
16572412.001
]
[Cites]
Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36
[
16331500.001
]
[Cites]
Bioconjug Chem. 2006 May-Jun;17(3):603-9
[
16704197.001
]
[Cites]
J Clin Invest. 2006 Jul;116(7):1994-2004
[
16767218.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1007-16
[
16763819.001
]
[Cites]
J Clin Oncol. 2006 Sep 10;24(26):4254-61
[
16908932.001
]
[Cites]
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8
[
17062694.001
]
[Cites]
Cancer Immun. 2007;7:6
[
17346028.001
]
[Cites]
Cancer Metastasis Rev. 2007 Mar;26(1):141-52
[
17333345.001
]
[Cites]
Clin Cancer Res. 2007 May 1;13(9):2557-67
[
17473184.001
]
[Cites]
Mayo Clin Proc. 2007 Jun;82(6):751-70
[
17550756.001
]
[Cites]
Int J Cancer. 2007 Sep 1;121(5):938-42
[
17487842.001
]
[Cites]
Int J Cancer. 2007 Oct 1;121(7):1585-92
[
17551919.001
]
[Cites]
J Clin Oncol. 2007 Aug 20;25(24):3621-7
[
17704411.001
]
[Cites]
Gene Ther. 2003 Jun;10(12):1018-25
[
12776159.001
]
(PMID = 18222534.001).
[ISSN]
1095-6859
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA80628; United States / NCI NIH HHS / CA / K12 CA090628-09
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
[Other-IDs]
NLM/ NIHMS123756; NLM/ PMC2707764
61.
Zuo ZG, Song HY, Xu C, Li J, Ni SC, Chen SQ:
[Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors].
Zhonghua Wai Ke Za Zhi
; 2009 Jul 1;47(13):988-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Combination of trans-
anal
intersphincteric resection and trans-abdominal total mesorectal excision for
anus
-retained ultra-low rectal tumors].
OBJECTIVE: To study the combination of trans-
anal
intersphincteric resection and transabdominal total mesorectal excision for
anus
-retained ultra-low rectal tumors.
METHODS: Clinical data of 34 ultra-low rectal tumor patients without external
anal
sphincter involved, who underwent the combination surgery, were retrospectively analyzed.
For pathological types, there were 23 cases of adenocarcinoma (9 well differentiated and 14 moderately differentiated), 1 papillary
carcinoma
, 2 rectal stromal tumor, 5 rectal villous adenoma with neoplasia and 3 giant villous adenoma.
For pathological stages, there were 18 cases at
stage
pTNM I, 5 at IIA, 1 at IIB, 4 at IIIA, 1 at III and for T grading, there were 15 cases at
stage
T1, 5 at T2, 8 at T3, 1 at T4.
Because of the dysfunction of bowel control, bowel frequency varied from 3 to 12 in the early
stage
after operation, but with the recovery
of anus
function, bowel frequency decreased and ranged form 1 to 5 times a day and the time of formed bowel control could be more than 5 min in 6-12 months after operation.
However, patients underwent total resection of internal
anal
sphincter still suffered from incontinence of loose stool after 1 year.
CONCLUSION: The combination of trans-
anal
ISR and trans-abdominal TME for
anus
-retained ultra low rectal tumor is not only coincident with radical tumor principle but also retains the function
of anus
, on the premise of the strict indication.
[MeSH-major]
Anal
Canal
/ surgery. Mesentery / surgery. Rectal Neoplasms / surgery
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19957808.001).
[ISSN]
0529-5815
[Journal-full-title]
Zhonghua wai ke za zhi [Chinese journal of surgery]
[ISO-abbreviation]
Zhonghua Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
62.
Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD:
Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
Clin Oncol (R Coll Radiol)
; 2009 Jun;21(5):376-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Size does matter: can we reduce the radiotherapy field size for selected cases of
anal
canal cancer
undergoing chemoradiation?
AIMS: Chemoradiation is the standard of care for the treatment of
anal
canal cancer
, with surgery reserved for salvage.
MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell
anal
canal cancer
were treated with chemoradiation using one phase of treatment throughout.
CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of
anal
canal cancer
with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
In future studies we would suggest that consideration is given as to whether omission of prophylactic inguinal nodal irradiation for early
stage
tumours should be explored.
[MeSH-major]
Anus
Neoplasms / radiotherapy.
Carcinoma
, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
[MeSH-minor]
Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal
Canal
. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19282157.001).
[ISSN]
0936-6555
[Journal-full-title]
Clinical oncology (Royal College of Radiologists (Great Britain))
[ISO-abbreviation]
Clin Oncol (R Coll Radiol)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
63.
Revuz J:
Hidradenitis suppurativa.
J Eur Acad Dermatol Venereol
; 2009 Sep;23(9):985-98
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Axillary and inguinal involvement is more common in females; peri-
anal
and buttocks localizations are prevalent in males.
The main complications are arthropathy,
carcinoma
.
Treatment depends upon the
stage
of the disease.
Early nodular lesions may be treated by antibiotics for acute
stage
; long-term antibiotics, zinc salts may be useful as maintenance treatment; anti-TNF drugs have been used in severe cases; systemic steroids, estrogens, anti-androgens, retinoids have been used as options with limited success.
Genetic Alliance.
consumer health - Hidradenitis Suppurativa
.
Genetics Home Reference.
consumer health - hidradenitis suppurativa
.
MedlinePlus Health Information.
consumer health - Hidradenitis Suppurativa
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19682181.001).
[ISSN]
1468-3083
[Journal-full-title]
Journal of the European Academy of Dermatology and Venereology : JEADV
[ISO-abbreviation]
J Eur Acad Dermatol Venereol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Anti-Bacterial Agents; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha
64.
Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL:
Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.
Mod Pathol
; 2007 Jun;20(6):656-67
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early
stage
in pancreatic adenocarcinoma progression.
When
cancer
was present in areas of chronic pancreatitis, this altered expression of alpha6beta4 integrin identified
the cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17415382.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21-CA102125
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Integrin alpha6beta4
[Other-IDs]
NLM/ NIHMS517144; NLM/ PMC4697742
65.
Selvindos PB, Ho YH:
Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
Dis Colon Rectum
; 2008 Nov;51(11):1710-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-
anal
anastomosis.
PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-
anal
anastomosis improves bowel function.
Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-
anal
anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
The indications were adenocarcinoma (n = 51), squamous-cell
carcinoma
of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
The adenocarcinomas were a median distance of 6 (3-12) cm from the
anal
verge.
The histologic grading or the adenocarcinoma patients were:
Stage I
, n = 14;
Stage
II, n = 23;
Stage
III, n = 11;
Stage
IV, n = 3.
The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the
anal
verge; a coloanal pull-through anastomosis was required in one patient who had a distal
cancer
.
Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced
stage
of cancer
(P = 0.047).
This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if
the cancer
was distal, the patient was obese, and the pelvis was narrow.
Further randomized, controlled studies that include assessing five-year
cancer
survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
[MeSH-major]
Adenocarcinoma / surgery.
Anal
Canal
/ surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18679748.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Interactive Tutorial
[Publication-country]
United States
66.
Oehler-Jänne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, Bonet M, Allal AS, Ciernik IF:
HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
J Clin Oncol
; 2008 May 20;26(15):2550-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HIV-specific differences in outcome of squamous cell
carcinoma
of the
anal
canal
: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
PURPOSE: To define clinical outcome after definitive chemoradiotherapy (CRT) of
anal carcinoma
in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
Local disease control (LC), relapse-free survival (RFS), overall survival (OS),
cancer
-specific survival (CSS), toxicity, and prognostic factors were investigated.
RESULTS: HIV-positive patients were younger (mean age, 48 v 62 years; P < .0005), predominantly male (93% v 25%; P < .0005), and with early-
stage
(P = .06) and large-cell histology (90% v 67%; P = .005) disease.
CONCLUSION: Long-term LC and acute toxicity represent major clinical challenges in HIV-positive patients with
anal carcinoma
.
[MeSH-major]
Antiretroviral Therapy, Highly Active.
Anus
Neoplasms / therapy.
Carcinoma
, Squamous Cell / therapy. HIV Infections / drug therapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS Medicines
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18427149.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
67.
Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D, Jurisica I, Lam WL, Tsao MS:
Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features.
Proc Natl Acad Sci U S A
; 2008 Jul 22;105(29):10155-60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Bronchioloalveolar
carcinoma
(BAC), a subtype of lung adenocarcinoma (ADC) without stromal, vascular, or pleural invasion, is considered an in situ tumor with a 100% survival rate.
Correlative gene expression analyses demonstrated a high percentage of them to be poor prognosis markers in early
stage
ADC.
Quantitative PCR also validated the amplification and overexpression of PDCD6 and TERT on chromosome 5p and the prognostic significance of PDCD6 in early
stage
ADC patients.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Genet. 2006 Sep;38(9):1043-8
[
16921376.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Oct 26;288(2):420-6
[
11606059.001
]
[Cites]
Genes Dev. 2001 Dec 15;15(24):3243-8
[
11751630.001
]
[Cites]
Bioinformatics. 2002 Jan;18(1):207-8
[
11836235.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Mar 15;291(5):1166-72
[
11883939.001
]
[Cites]
Mol Cell Biol. 2002 Jun;22(12):4094-100
[
12024023.001
]
[Cites]
Nat Med. 2002 Aug;8(8):816-24
[
12118244.001
]
[Cites]
Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7
[
12440623.001
]
[Cites]
Biochim Biophys Acta. 2002 Nov 4;1600(1-2):68-73
[
12445461.001
]
[Cites]
Eur J Cardiothorac Surg. 2003 Mar;23(3):409-14
[
12614815.001
]
[Cites]
Am J Pathol. 2003 Jul;163(1):81-9
[
12819013.001
]
[Cites]
Eur J Cancer. 2003 Sep;39(13):1936-47
[
12932674.001
]
[Cites]
Cancer Cell. 2003 Aug;4(2):111-20
[
12957286.001
]
[Cites]
J Clin Oncol. 2004 Mar 15;22(6):1103-9
[
15020612.001
]
[Cites]
Am J Surg Pathol. 2004 Feb;28(2):198-206
[
15043309.001
]
[Cites]
BMC Bioinformatics. 2004 Feb 9;5:13
[
15040819.001
]
[Cites]
Bioessays. 2004 Nov;26(11):1164-74
[
15499579.001
]
[Cites]
Cancer. 1995 Jan 1;75(1 Suppl):191-202
[
8000996.001
]
[Cites]
Cancer. 1995 Jun 15;75(12):2844-52
[
7773933.001
]
[Cites]
Science. 1996 Jan 26;271(5248):521-5
[
8560270.001
]
[Cites]
Int J Cancer. 1997 Jul 3;72(1):1-22
[
9212216.001
]
[Cites]
Biochem J. 1997 Dec 1;328 ( Pt 2):718-20
[
9441591.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5211-6
[
9560255.001
]
[Cites]
J Biol Chem. 1999 Jan 15;274(3):1533-40
[
9880530.001
]
[Cites]
Am J Clin Pathol. 1999 May;111(5):610-22
[
10230351.001
]
[Cites]
Exp Biol Med (Maywood). 2004 Dec;229(11):1090-6
[
15564434.001
]
[Cites]
Bioinformatics. 2004 Dec 12;20(18):3636-7
[
15201182.001
]
[Cites]
Cell. 2005 Jun 17;121(6):823-35
[
15960971.001
]
[Cites]
Biotechnol Lett. 2005 Jul;27(14):1011-5
[
16132846.001
]
[Cites]
Clin Cancer Res. 2005 Sep 1;11(17):6177-85
[
16144918.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Jan;45(1):11-9
[
16130125.001
]
[Cites]
Br J Cancer. 2006 May 22;94(10):1452-9
[
16641908.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5330-7
[
16707459.001
]
[Cites]
N Engl J Med. 2006 Aug 10;355(6):570-80
[
16899777.001
]
[Cites]
Nat Rev Cancer. 2007 Feb;7(2):79-94
[
17251915.001
]
[Cites]
Anal Cell Pathol. 2001;22(3):111-21
[
11455030.001
]
[Cites]
Ann Thorac Surg. 2000 Mar;69(3):893-7
[
10750779.001
]
[Cites]
Lung Cancer. 2000 Sep;29(3):179-88
[
10996420.001
]
[Cites]
J Thorac Cardiovasc Surg. 2001 Jan;121(1):42-7
[
11135158.001
]
[Cites]
J Biol Chem. 2001 Apr 27;276(17):14053-8
[
11278427.001
]
[Cites]
Nature. 2001 Apr 26;410(6832):1111-6
[
11323676.001
]
[Cites]
J Biol Chem. 2001 Feb 16;276(7):4677-82
[
11076956.001
]
[Cites]
Nat Cell Biol. 2001 Sep;3(9):839-43
[
11533664.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
[
11707567.001
]
(PMID = 18632575.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
eng
[Databank-accession-numbers]
GEO/ GSE11945
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / PDCD6 protein, human; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
[Other-IDs]
NLM/ PMC2465804
68.
Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, Freeman A, Wollenschlaeger A, Ralph DJ, Stoeber K, Williams GH:
DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.
Clin Cancer Res
; 2009 Dec 01;15(23):7335-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile
carcinoma
.
We have analyzed replication licensing factors (RLF), together with DNA ploidy status, to investigate their role in progression of penile squamous cell
carcinoma
and to assess their utility as novel prognostic tools.
Accelerated cell cycle progression was linked to increasing tumor size,
stage
, and depth of invasion.
Our results also identify the DNA replication initiation pathway as a potentially attractive therapeutic target in penile squamous cell
carcinoma
.
[MeSH-major]
Aneuploidy.
Carcinoma
/ genetics.
Carcinoma
/ therapy. Gene Expression Regulation, Neoplastic. Penile Neoplasms / genetics. Penile Neoplasms / therapy
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 2009 Mar 24;100(6):959-70
[
19240714.001
]
[Cites]
Br J Cancer. 2005 Nov 28;93(11):1295-300
[
16278669.001
]
[Cites]
IARC Sci Publ. 1992;(120):45-173
[
1284606.001
]
[Cites]
J Urol. 1993 Mar;149(3):492-7
[
8437253.001
]
[Cites]
Nat Chem Biol. 2008 Jun;4(6):331-2
[
18488006.001
]
[Cites]
Br J Cancer. 2009 Apr 7;100(7):1128-34
[
19293805.001
]
[Cites]
Clin Cancer Res. 1999 Aug;5(8):2121-32
[
10473096.001
]
[Cites]
J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9
[
12122098.001
]
[Cites]
J Urol. 2006 May;175(5):1700-4; discussion 1704-5
[
16600735.001
]
[Cites]
Acta Neuropathol. 2007 Feb;113(2):119-27
[
17160531.001
]
[Cites]
BJU Int. 2006 Sep;98(3):526-31
[
16925747.001
]
[Cites]
Clin Cancer Res. 2001 Sep;7(9):2712-8
[
11555583.001
]
[Cites]
Br J Urol. 1993 Dec;72(6):941-5
[
8306161.001
]
[Cites]
Nat Rev Cancer. 2005 Nov;5(11):845-56
[
16239904.001
]
[Cites]
Am J Surg Pathol. 1998 Jun;22(6):755-61
[
9630184.001
]
[Cites]
Clin Cancer Res. 2009 Apr 1;15(7):2417-25
[
19318489.001
]
[Cites]
Nat Rev Cancer. 2006 Sep;6(9):735-41
[
16915294.001
]
[Cites]
Eur Urol. 2004 Jul;46(1):1-8
[
15183542.001
]
[Cites]
Br J Cancer. 2004 Jul 19;91(2):262-9
[
15199392.001
]
[Cites]
Urol Clin North Am. 1992 May;19(2):247-56
[
1574815.001
]
[Cites]
Exp Cell Res. 2005 Sep 10;309(1):56-67
[
16005865.001
]
[Cites]
EMBO J. 1998 Dec 15;17(24):7219-29
[
9857179.001
]
[Cites]
J Pathol. 2005 Feb;205(3):318-28
[
15682442.001
]
[Cites]
J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86
[
15522891.001
]
[Cites]
Trends Cell Biol. 2002 Feb;12(2):72-8
[
11849970.001
]
[Cites]
J Urol. 2005 Mar;173(3):816-9
[
15711276.001
]
[Cites]
Clin Cancer Res. 2007 Oct 15;13(20):6153-61
[
17947481.001
]
[Cites]
Curr Opin Cell Biol. 2007 Dec;19(6):672-9
[
18032010.001
]
[Cites]
J Urol. 2006 Jun;175(6):2103-8; discussion 2108
[
16697813.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7
[
9843993.001
]
[Cites]
Exp Cell Res. 2007 Oct 15;313(17):3789-99
[
17689530.001
]
[Cites]
Br J Urol. 1993 Nov;72(5 Pt 2):817-9
[
8281416.001
]
[Cites]
Anal Cell Pathol. 1998;17(4):189-200
[
10391371.001
]
[Cites]
Br J Cancer. 2004 Aug 16;91(4):714-9
[
15266314.001
]
[Cites]
Nat Rev Cancer. 2008 Oct;8(10):799-806
[
18756287.001
]
[Cites]
Gut. 2002 Mar;50(3):373-7
[
11839717.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86
[
15928711.001
]
[Cites]
Annu Rev Biochem. 2002;71:333-74
[
12045100.001
]
[Cites]
J Surg Oncol. 2008 May 1;97(6):487-95
[
18425779.001
]
[Cites]
Am J Pathol. 2002 Jul;161(1):267-73
[
12107111.001
]
[Cites]
Br J Cancer. 2007 May 7;96(9):1384-93
[
17406359.001
]
[Cites]
J Clin Oncol. 2003 Dec 1;21(23):4306-13
[
14645419.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2510-7
[
15814627.001
]
[Cites]
Nat Rev Cancer. 2003 Mar;3(3):217-26
[
12612656.001
]
[Cites]
Lancet. 1999 Oct 30;354(9189):1524-5
[
10551502.001
]
[Cites]
Br J Cancer. 2003 Sep 15;89(6):1048-54
[
12966424.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2855-64
[
18843031.001
]
[Cites]
Anal Quant Cytol Histol. 2007 Aug;29(4):185-98
[
17879626.001
]
[Cites]
Ann Surg. 1921 Feb;73(2):141-60
[
17864409.001
]
[Cites]
Br J Cancer. 2008 May 6;98(9):1548-54
[
18414413.001
]
[Cites]
J Cell Sci. 2001 Jun;114(Pt 11):2027-41
[
11493639.001
]
(PMID = 19920109.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United Kingdom / Cancer Research UK / / A6263
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
[Other-IDs]
NLM/ PMC2788529; NLM/ UKMS27727
69.
Wortham M, He L, Gyamfi M, Copple BL, Wan YJ:
The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet.
Dig Dis Sci
; 2008 Oct;53(10):2761-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
By mechanisms that are not completely understood, this disease may progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular
carcinoma
(HCC).
The occurrence of SAMe depletion at this early, benign
stage
of NASH development in db/db mice with fatty liver suggests that SAMe supplementation may be (A) targeted to individuals susceptible to NASH (i.e., NAFLD patients) and (B) preventative of NASH before substantial liver injury has occurred.
MedlinePlus Health Information.
consumer health - Hepatitis
.
MedlinePlus Health Information.
consumer health - Obesity
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
(L)-Methionine
.
Hazardous Substances Data Bank.
CHOLINE CHLORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hepatology. 1995 Oct;22(4 Pt 1):1310-5
[
7557886.001
]
[Cites]
Dig Dis Sci. 2008 Mar;53(3):767-76
[
17710550.001
]
[Cites]
Hepatology. 1996 Nov;24(5):1090-7
[
8903381.001
]
[Cites]
Pharmacol Ther. 1997;73(3):265-80
[
9175157.001
]
[Cites]
Am J Physiol. 1998 Jul;275(1 Pt 1):G14-21
[
9655679.001
]
[Cites]
Hepatology. 1999 May;29(5):1471-8
[
10216131.001
]
[Cites]
J Hepatol. 1999 Jun;30(6):1081-9
[
10406187.001
]
[Cites]
J Biol Chem. 1957 May;226(1):497-509
[
13428781.001
]
[Cites]
PLoS Biol. 2005 Apr;3(4):e101
[
15760270.001
]
[Cites]
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112
[
16447287.001
]
[Cites]
J Biochem Mol Toxicol. 2006;20(1):39-47
[
16498637.001
]
[Cites]
J Clin Invest. 2006 Mar;116(3):615-22
[
16511594.001
]
[Cites]
J Clin Invest. 2000 Apr;105(8):1067-75
[
10772651.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2000 Jul;279(1):G178-85
[
10898761.001
]
[Cites]
J Hepatol. 2000 Dec;33(6):907-14
[
11131452.001
]
[Cites]
Semin Liver Dis. 2001;21(1):89-104
[
11296700.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5560-5
[
11320206.001
]
[Cites]
Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):679-90
[
12406439.001
]
[Cites]
Semin Liver Dis. 2004 Feb;24(1):3-20
[
15085483.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1035-43
[
15256362.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Biochem Pharmacol. 1978 May 15;27(10):1431-3
[
697884.001
]
[Cites]
FEBS Lett. 1982 Aug 23;145(2):293-7
[
7128827.001
]
[Cites]
Hepatology. 1988 Jan-Feb;8(1):65-8
[
3338721.001
]
[Cites]
Scand J Gastroenterol. 1989 May;24(4):407-15
[
2781235.001
]
[Cites]
Hepatology. 1990 Feb;11(2):165-72
[
2307395.001
]
[Cites]
Hepatology. 1990 Nov;12(5):1106-10
[
2227807.001
]
[Cites]
Hepatology. 1992 Feb;15(2):297-301
[
1735533.001
]
[Cites]
Cancer Res. 1992 Sep 15;52(18):4979-86
[
1516054.001
]
[Cites]
Science. 1993 Jan 1;259(5091):87-91
[
7678183.001
]
[Cites]
Hepatology. 1995 Jan;21(1):207-14
[
7806156.001
]
[Cites]
Biochem Biophys Res Commun. 1994 Dec 30;205(3):1748-54
[
7811261.001
]
[Cites]
Int J Mol Med. 2006 Sep;18(3):433-9
[
16865227.001
]
[Cites]
J Lipid Res. 2006 Oct;47(10):2280-90
[
16829692.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5223-8
[
17360356.001
]
[Cites]
Hepatology. 2007 May;45(5):1306-12
[
17464973.001
]
[Cites]
Hepatology. 2007 Jun;45(6):1366-74
[
17476695.001
]
[Cites]
Nature. 1996 Feb 15;379(6566):632-5
[
8628397.001
]
(PMID = 18299981.001).
[ISSN]
0163-2116
[Journal-full-title]
Digestive diseases and sciences
[ISO-abbreviation]
Dig. Dis. Sci.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA53596; United States / NIAAA NIH HHS / AA / R01 AA014147; United States / NCRR NIH HHS / RR / P20 RR021940; United States / NIAAA NIH HHS / AA / AA14147; United States / NCI NIH HHS / CA / R01 CA053596
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
7LP2MPO46S / S-Adenosylmethionine; AE28F7PNPL / Methionine; GAN16C9B8O / Glutathione; N91BDP6H0X / Choline
[Other-IDs]
NLM/ NIHMS565666; NLM/ PMC3991247
70.
Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A:
Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
Dis Colon Rectum
; 2009 Apr;52(4):624-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcomes and prognostic factors for squamous-cell
carcinoma
of the
anal
canal
: analysis of patients from the National
Cancer
Data Base.
PURPOSE: The objective of this study was to assess survival and prognostic factors for
anal carcinoma
in the population.
METHODS: Patients with squamous-cell
carcinoma
of the
anal
canal
were identified from the National
Cancer
Data Base (1985-2000).
Concordance was calculated to assess agreement between American Joint Committee on
Cancer
stage
and actual outcome.
RESULTS: Nineteen thousand one hundred ninety-nine patients with
anal carcinoma
were identified (
Stage I
, 25.3 percent;
Stage
II, 51.8 percent;
Stage
III, 17.1 percent;
Stage
IV, 5.7 percent).
The American Joint Committee on
Cancer
(6th edition) staging system provided good survival discrimination by
stage
: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
On multivariable analysis, patients with
anal carcinoma
had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T
stage
tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell
carcinoma
of the
anal
canal
.
[MeSH-major]
Anus
Neoplasms / mortality.
Carcinoma
, Squamous Cell / mortality
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19404066.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
71.
Costa AF, Altemani A, Vékony H, Bloemena E, Fresno F, Suárez C, Llorente JL, Hermsen M:
Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type.
Anal Cell Pathol (Amst)
; 2010;33(5):217-28
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: genome-wide DNA copy number changes were analyzed by microarray CGH in ACC-HGT, 4 with transformation into moderately differentiated adenocarcinoma (MDA) and two into poorly differentiated
carcinoma
(PDC), 5 solid ACC.
CONCLUSION: ACC-HGT may not necessarily reflect a more advanced
stage
of tumor progression, but rather a transformation to another histological form in which the poorly differentiated forms (PDC) presents a genetic complexity similar to the solid ACC.
[MeSH-major]
Carcinoma
, Adenoid Cystic / genetics.
Carcinoma
, Adenoid Cystic / pathology. Cell Transformation, Neoplastic / pathology. Gene Expression Profiling
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Cell Oncol (Dordr). 2011 Aug;34(4):407-8
(PMID = 20978318.001).
[ISSN]
2210-7185
[Journal-full-title]
Analytical cellular pathology (Amsterdam)
[ISO-abbreviation]
Anal Cell Pathol (Amst)
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
[Other-IDs]
NLM/ PMC4605554
72.
Engin G:
Endosonographic imaging of anorectal diseases.
J Ultrasound Med
; 2006 Jan;25(1):57-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: Rectal
carcinoma
appears on endorectal sonography as a low-echogenicity lesion that abruptly interrupts the normal sequence of layers.
The internal
anal
sphincter is seen very clearly on endoanal sonography, and it is easy to appreciate atrophy and small tears of this sphincter.
Endoanal sonography cannot accurately show thinning of the external
anal
sphincter.
CONCLUSIONS: Endosonography can accurately
stage
primary rectal tumors and assess the internal
anal
sphincter.
However, magnetic resonance imaging can be used a complementary modality to endosonography, especially for evaluation of external
anal
sphincter atrophy and deep pelvic inflammation.
[MeSH-major]
Anus
Diseases / ultrasonography. Endosonography / methods. Rectal Diseases / ultrasonography
MedlinePlus Health Information.
consumer health - Anal Disorders
.
MedlinePlus Health Information.
consumer health - Rectal Disorders
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16371556.001).
[ISSN]
0278-4297
[Journal-full-title]
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
[ISO-abbreviation]
J Ultrasound Med
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
68
73.
Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB:
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
PLoS One
; 2009;4(5):e5583
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian
carcinoma
and worsened prognosis.
Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian
cancer
cells, implicating LPA in the initiation and progression of ovarian
cancer
.
However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian
cancer
.
METHODOLOGY AND PRINCIPAL FINDINGS: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian
cancer
cells for 24 h to mimic long-term stimulation in the tumor microenvironment.
The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian
carcinoma
.
Hierarchical clustering of ovarian
cancer
patient specimens demonstrated that the signature is associated with worsened prognosis.
They have a higher frequency of
stage
IIIc serous
carcinoma
and a greater proportion is deceased.
Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian
carcinoma
.
Knockdown of claudin-1 expression in ovarian
cancer
cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
CONCLUSIONS: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian
cancer
that predicts a worse prognosis.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 1999 Nov;5(11):3704-10
[
10589790.001
]
[Cites]
Mol Oncol. 2008 Jun;2(1):54-69
[
19081821.001
]
[Cites]
Anal Biochem. 2001 Mar15;290(2):302-13
[
11237333.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
[
11309499.001
]
[Cites]
Gynecol Oncol. 2001 May;81(2):291-300
[
11330965.001
]
[Cites]
Bioinformatics. 2001 Jun;17(6):520-5
[
11395428.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64
[
12069836.001
]
[Cites]
Cancer Res. 2003 Mar 1;63(5):1073-82
[
12615725.001
]
[Cites]
Nat Rev Cancer. 2003 Aug;3(8):582-91
[
12894246.001
]
[Cites]
Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii
[
12959182.001
]
[Cites]
Genome Biol. 2003;4(10):R70
[
14519205.001
]
[Cites]
Nucleic Acids Res. 2003 Dec 15;31(24):e154
[
14654707.001
]
[Cites]
Endocrinology. 2004 Jun;145(6):2929-40
[
14988385.001
]
[Cites]
J Cell Biochem. 2004 Aug 15;92(6):1115-40
[
15258897.001
]
[Cites]
Arterioscler Thromb. 1993 Nov;13(11):1662-7
[
8218108.001
]
[Cites]
Biochem J. 1998 Mar 15;330 ( Pt 3):1107-14
[
9494074.001
]
[Cites]
Ann Oncol. 1998 Apr;9(4):437-42
[
9636836.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
[
9843981.001
]
[Cites]
Gynecol Oncol. 1998 Dec;71(3):364-8
[
9887232.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54
[
10339573.001
]
[Cites]
Nat Rev Cancer. 2005 May;5(5):355-66
[
15864277.001
]
[Cites]
Oncogene. 2005 Jul 7;24(29):4672-87
[
15940270.001
]
[Cites]
J Clin Invest. 2005 Jul;115(7):1765-76
[
15965503.001
]
[Cites]
Cancer Res. 2005 Nov 1;65(21):9603-6
[
16266975.001
]
[Cites]
Cancer Res. 2005 Nov 15;65(22):10602-12
[
16288054.001
]
[Cites]
Cancer Res. 2006 Feb 1;66(3):1354-62
[
16452189.001
]
[Cites]
Cancer Res. 2006 Mar 1;66(5):2740-8
[
16510595.001
]
[Cites]
Matrix Biol. 2006 May;25(4):223-31
[
16503403.001
]
[Cites]
J Biol Chem. 2006 Aug 11;281(32):22786-93
[
16782709.001
]
[Cites]
Eur J Cancer. 2006 Nov;42(16):2846-54
[
16996261.001
]
[Cites]
Gynecol Oncol. 2006 Nov;103(2):591-8
[
16797678.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11
[
17346539.001
]
[Cites]
Am J Clin Pathol. 2007 Jun;127(6):928-37
[
17509990.001
]
[Cites]
Expert Rev Mol Med. 2007;9(28):1-18
[
17935635.001
]
[Cites]
Hum Pathol. 2008 May;39(5):747-57
[
18439941.001
]
[Cites]
Adv Exp Med Biol. 2008;617:23-40
[
18497028.001
]
[Cites]
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
[
18698038.001
]
[Cites]
Biochim Biophys Acta. 2008 Sep;1781(9):547-57
[
18501205.001
]
[Cites]
J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42
[
19001604.001
]
[Cites]
Clin Cancer Res. 2000 Jun;6(6):2482-91
[
10873103.001
]
(PMID = 19440550.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Lysophospholipids; 0 / Membrane Proteins; 22002-87-5 / lysophosphatidic acid
[Other-IDs]
NLM/ PMC2679144
74.
Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F:
Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
Mol Oncol
; 2007 Jun;1(1):97-119
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting
cancer
at an earlier
stage
.
The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine
carcinoma
in situ.
SA with apocrine metaplasia, i.e. apocrine adenosis (AA), presents with a higher degree of atypical apocrine hyperplasia, and these lesions are believed to be precursors of apocrine
carcinoma
, in situ and invasive.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Cell Sci. 2002 Jan 1;115(Pt 1):39-50
[
11801722.001
]
[Cites]
Mod Pathol. 1994 Oct;7(8):813-8
[
7838835.001
]
[Cites]
Ann Surg. 2002 Dec;236(6):785-93; discussion 793
[
12454517.001
]
[Cites]
Breast Cancer Res Treat. 2007 Jul;104(1):75-85
[
17009105.001
]
[Cites]
J Cell Biol. 1997 Dec 29;139(7):1873-84
[
9412479.001
]
[Cites]
Adv Anat Pathol. 2004 Jan;11(1):1-9
[
14676636.001
]
[Cites]
Eur J Radiol. 2005 Apr;54(1):6-14
[
15797289.001
]
[Cites]
Am J Pathol. 1983 Feb;110(2):105-12
[
6130702.001
]
[Cites]
Br J Cancer. 1995 Jan;71(1):146-9
[
7819031.001
]
[Cites]
Radiographics. 1999 Oct;19 Spec No:S80-3
[
10517446.001
]
[Cites]
Cancer Cell. 2006 Dec;10(6):459-72
[
17157787.001
]
[Cites]
Am J Surg. 1990 May;159(5):473-8
[
2334010.001
]
[Cites]
J Pathol. 2004 Mar;202(3):274-85
[
14991892.001
]
[Cites]
Virchows Arch. 1998 Mar;432(3):255-60
[
9532005.001
]
[Cites]
Am J Surg. 1993 Sep;166(3):237-43
[
8368433.001
]
[Cites]
J Cutan Pathol. 1999 Mar;26(3):113-8
[
10235375.001
]
[Cites]
Nature. 1999 Apr 22;398(6729):708-13
[
10227293.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23
[
16835330.001
]
[Cites]
Mol Cell Proteomics. 2005 Apr;4(4):555-69
[
15644556.001
]
[Cites]
Mol Oncol. 2007 Jun;1(1):26-41
[
19383285.001
]
[Cites]
Anticancer Res. 1988 Nov-Dec;8(6):1217-22
[